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WITH THYMIC TUMORS 
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University of Pennsylvania, Philadelphia/UNITED STATES 
OF AMERICA 
 
Thymoma is associated with a diverse range of autoimmune 
neurological disorders. The most well-known and common 
manifestation involves antibodies to the nicotinic 
acetylcholine receptor in patients with myasthenia gravis. It is 
estimated that 20% of patients with myasthenia gravis have 
thymic tumors and 15-40% of patients with thymoma may 
have neurological syndromes. While the relationship 
between myasthenia and thymoma has been studied 
extensively, the other paraneoplastic disorders associated 
with thymoma have drawn less attention. The second most 
common autoimmune neurological disorder associated with 
thymoma (after myasthenia) is Isaacs’ syndrome (acquired 
neuromyotonia), a syndrome of peripheral nerve 
hyperexcitability resulting in diffuse muscle fasciculations, 
hyperhidrosis, and muscle spasms. Encephalitis is 
somewhat less common and typically manifests as subacute 
memory impairment, seizures, confusion, and behavioral 
changes. Morvan’s syndrome is also associated with 
thymoma and involves a combination of peripheral and 
central nervous system symptoms: fasciculations, 
hallucinations, cramps/muscle spasms, insomnia, and 
encephalitis. Patients with Isaacs’ syndrome, Morvan’s 
syndrome, or encephalitis may have antibodies to the 
voltage-gated potassium channel (VGKC) complex, but 
these antibodies rarely, if ever, actually target potassium 
channel subunits directly. Rather the main target antigens 
are two proteins associated with Kv1 potassium channels, 
LGI1 and Caspr2. (There may also be other, as yet 
unknown, proteins associated with the VGKC complex that 
are antigens in some cases). LGI1 is a secreted synaptic 
protein that organizes potassium channels and other proteins 
at CNS synapses. Patients with LGI1 antibodies have 
encephalitis, usually respond well to immunotherapy, and do 
not typically have associated tumors. Caspr2 is an axonal 
protein critical for organizing VGKCs into the correct 
subcellular domain, the juxtaparanodes, on myelinated 
axons of both the CNS and PNS. It is unsurprising therefore 
that patients with Caspr2 antibodies may have PNS (Isaacs’ 
syndrome), CNS (encephalitis) or both CNS and PNS 
manifestations (e.g. Morvan’s syndrome). Patients with 
Caspr2 antibodies may have PNS and CNS symptoms in 
either order, often months or years apart, or concurrently. 
Thymoma is particularly associated with Caspr2 antibodies 
and not LGI1 antibodies. In addition to VGKC complex 
antibodies, patients with thymoma may rarely develop 
encephalitis associated with paraneoplastic antibodies to Hu, 
CRMP-5, Ma, or other antigens. In these disorders the 
antibodies are probably not directly pathogenic and more 
likely represent a T-cell mediated response targeting 
neurons. The prognosis is correspondingly poor. Patients 
with thymoma may also present with autoimmune peripheral 
neuropathy, pain syndromes, and/or autonomic dysfunction 
(including Horner’s syndrome). And some patients may have 
multiple autoimmune neurological syndromes. For example, 
patients with Morvan’s syndrome due to Caspr2 antibodies 
may have co-existing myasthenia gravis with acetylcholine 
receptor antibodies. In these cases the combination of 
diffuse fasciculations from Morvan’s syndrome and bulbar 
weakness from myasthenia may create a confusing clinical 
picture that could be mistaken for motor neuron disease 
(ALS). Polymyositis, autoimmune muscle inflammation, may 
occur in the setting of thymoma, and may be comorbid with 
myasthenia gravis. Stiff person syndrome, a disorder of 
hyperexcitability at the spinal cord level resulting in painful 
muscle spasms and debilitating increase in muscle tone, 
may also occur in the setting of thymoma. Stiff person 
syndrome is sometimes associated with antibodies to 
GAD65. Isaacs’ syndrome is usually treated symptomatically 
with voltage-gated sodium channel antagonists such as 
phenytoin or carbamazepine. In severe cases 
immunotherapy with steroids, IVIg and other agents is 
required. For encephalitis or Morvan’s syndrome associated 
with Caspr2 antibodies, treatment with steroids, IVIg and 
other immunotherapies should begin promptly. Most patients 
with Caspr2 antibodies respond to immunotherapy and 
recover to normal or to only mild disability over a period of 
weeks to months. However, relapses may occur with 
tapering of immunotherapy. Immunotherapy is also attempts 
for patients with classical paraneoplastic antigens (Hu, Ma, 
etc.) but is less likely to be effective. Tumor therapy is also 
any important consideration in all patients with thymoma and 
may help associated autoimmune disorders. The optimal 
treatments for all of these disorders have not been 
established. In summary, thymic tumors are associated with 
myasthenia gravis, encephalitis, Isaacs’ syndrome, Morvan’s 
syndrome, and other autoimmune neurological syndromes. 
Testing for antibodies to the nicotinic acetyl choline receptor, 
VGKC complex and other paraneoplastic antibodies may 
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assist with diagnosis. Due to these associations clinicians 
should be vigilant for signs of myasthenia gravis, Isaacs’ 
syndrome, encephalitis and other neurological 
manifestations in patients with thymoma. These disorders 
may emerge at any point in the disease course and cause 
significant morbidity but often respond to immunotherapy. 
Conversely, the identification of myasthenia gravis or the 
other syndromes should prompt careful screening for 
thymoma and urgent treatment of any thymic tumor.  
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Myasthenia gravis (MG) is a disease of immune mediated 
attack on the postsynaptic membrane of the neuromuscular 
junction causing weakness of skeletal muscles. This illness 
mostly occurs in adults and typically affects the eyes, 
oropharynx, respiratory, and axial muscles. The weakness is 
reversible with a variety of treatments. As treatment has 
evolved over the last 80 years, physicians have developed 
instruments to measure patient improvement. This 
discussion is a brief summary of the most salient measuring 
tools available. 
 
Over 50 years ago, the World Health Organization defined 
quality of life, and more specifically, health related quality of 
life (HR-QoL) in its charter. The modern concept, a direct 
descendent of the original definition takes many forms, one 
of which is the perception of and satisfaction with the 
individual’s current state of health with regards to physical, 
psychological and social well being regardless of the 
presence or absence of disease. An ideal HR-QoL 
instrument would capture these three domains and 
summarize them in a single metric. Using this definition, it is 
apparent that the first instruments in the published literature 
measuring treatment responses in patients with myasthenia 
gravis didn’t include many of these domains. Instead, the 
concentration was on the physician’s observations of the 
disease’s response to treatment. The earliest and simplest 
category was achievement of remission. Later, 
categorization was based on various changes in muscle 
strength or eye-lid ptosis with cholinesterase inhibitors or 
immunosuppression. Probably the best-known iteration of 
these grading systems in the modern period is the 
Myasthenia Gravis Foundation of America (MGFA) Clinical 
Classification.1 To address functional status in clinical trials 
some investigators used non-MG specific scales, e.g. a 
modified Rankin score or the WHO Disability Assessment 
Schedule (WHO-DADS). With the advent in the 1980’s of 
summative rating scales in MG, investigators noted the poor 
correlation with the grading and classification systems then 
available. The MGFA’s Medical Scientific Advisory Board 
emphasized that the MGFA Clinical Classification should not 
be used to measure a change in severity because of the 
availability of ordinal severity rating scales. Some of these 
summative rating scales classify patients by physical 
examination findings, e.g. the Manual Muscle Test for MG or 
Mantegazza’s et al. MG Score. While these instruments 
provide invaluable information regarding a patient’s physical 
response to treatment, they do not address the critical 
domains of mental and social well being that may be equally, 
and in some cases more affected by MG. To that end, 
investigators developed scales to address impairment of the 
HR-QoL. Initially, non-MG specific scales were used, e.g. the 
Short Form (36) health survey (SF-36), a self-administered 
survey of emotional and physical factors. These proved 
insensitive to the focal weakness occurring in MG. For 
example, neither ocular nor bulbar weakness resulted in 
deterioration in HR-QoL when these scales were used in 
several studies. 2,3 Hence the development of the MG-
specific questionnaire (MGQ), a self-administered, validated 
measure of functional status. Another is the MG Composite 
scale. This region specific targeted approach is theoretically 
attractive but has yielded mixed results. When patients were 
asked to choose 2 of the symptoms most bothersome to 
them out of the 10 listed on the MG Composite scale, they 
most frequently chose two of the following: ptosis, double 
vision and trouble swallowing. However, this “choose 2” 
paradigm didn’t correlate well (lower sensitivity and 
specificity) with the clinical improvement detected by the total 
score of the MG Composite score.4 While investigators have 
been advised not to use the “choose 2” paradigm, it is 
apparent that further clarification is needed as to why this 
tool is unhelpful. Perhaps, the scale is too insensitive to 
patients’ needs or the therapy is inadequate. In further 
attempts at measuring HR-QoL, more multidimensional 
instruments are needed that measure tolerability of 
dysfunction – ptosis to a carpenter may affect her more than 
it does a neurologist. Such instruments should measure the 
impact of disease on the physical, psychological, social and 
occupational well being of an individual. One such tool is the 
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Individualized Neuromuscular QOL (INQoL), another is an 
MG-specific measure of QOL developed for a treatment trial. 
These questionnaires are 45 and 60 questions long 
respectively. The surveys assess domains of mobility, 
emotional well-being, general contentment, thinking, fatigue, 
and additional concerns. In one study, there was some 
correlation with some of the physical score instrument and a 
better performance than the SF-36. To simplify and allow use 
in daily clinical practice a 15 item MG-specific QOL (MG-
QOL 15) tool drawn from the 60 question long MG QOLhas 
been developed. This tool correlated highly with the 60 item 
QOL for the physical domains, and it correlated well with the 
social domains of the SF-36.5 It also correlated with MGQ, 
MG-MMT and MG-ADL. The MG-QOL 15 demonstrated high 
sensitivity and it has been validated in an 11-center 
prospective study of 175 patients with MG.5 Much 
improvement has occurred in the last few decades in 
measuring treatment responses of the whole individual with 
myasthenia gravis. Much work remains to make these 
measuring instruments more refined, and simultaneously 
more comprehensive. They also have to be easy to 
complete, calculate and interpret.  
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Patient registries are organized systems that use 
observational methods to collect uniform data and have 
proven to highly effective in establishing platforms for 
planning clinical trials, assessment of patient characteristics, 
performing economic analyses, and providing a conduit for 
patient education. After decades of patient requests, the MG 
Foundation of America sponsored the development of a 
registry based on patient based submission of data. Using as 
a model a highly successful of registry dedicated to multiple 
sclerosis, the organizing committee obtained commentary 
from physicians involved in clinical care and research, 
patients, nurses, the ITMG, and administration of the MG 
Foundation to finalize the registry questions. The 24 page 
questionnaire covering demographic, insurance, diagnostic, 
quality of life, and treatment issues will require web-based 
data entry, hosted by the University of Alabama at 
Birmingham. Investigators will be able to access de-identified 
data after Ethics or Internal Review Board approval. 
Individuals from across the world could submit information to 
the system, but at present the registry is highly biased 
towards US healthcare issues. The MG Patient Registry was 
activated in July of 2013. Initial response to the MG Registry 
will be presented. Yearly newsletters will be sent to 
participants that provide summaries of data acquisition as 
well as MG related educational information. 
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Thymomas are rare neoplasms, with an incidence of 0.13 
per 100.000. Thymomas are distiguished by their indolent 
and slow growing nature and by a relatively low rate of 
recurrence. Another distinguishing factor is the association of 
thymomas and autoimmune diseases. Between 30% and 
50% of all patients with thymoma either will be diagnosed 
with an autoimmune syndrome, myasthenia gravis being the 
most common. Other less common autoimmune diseases 
include systemic lupus erythematosus, red cell aplasia, 
bullous pemphigus, and syndrome of inappropriate 
antidiuretic hormone secretion. Even more rarely, thymomas 
are associated with thyroiditis, polymyositis, rheumatoid 
arthritis, encephalitis, and ulcerative colitis. Less often 
recognized is the association of thymoma and 
immunodeficiency, often called Good’s syndrome. Although 
lacking clear diagnostic criteria, Good’s syndrome often 
presents with hypogammaglobulinemia, decreased number 
of circulating B and T cells, and abnormal CD4:CD8 ration. 
Patients with thymoma also have a higher incidence of 
extrathymic cancers. This is attributed to decreased or 
inappropriate immunosurveillance a T cell lymphocyte 
function. The most common extrathymic cancers are 
lymphomas, breast carcinomas, prostate cancer, and lung 
cancer. Interestingly, the incidence of extrathymic cancers is 
increased prior to the diagnosis of thymoma. Also 
autoimmune diseases and secondary neoplasms appear to 
be more common in World Health Organization (WHO) type 
B thymomas. The thymus is central to the development and 
selection of T cell lymphocytes (TCL) by releasing TCL 
attracting hormones. TCL’s enter the cortical thymus where 
positive selection occurs. Only TCL’s that bind to self Major 
Histocompatibility Complex (MHC) antigens are selected and 
allowed to proceed to the medulla. In the medulla, the 
important negative selection occurs and TCL reacting to self 
tissue specific antigens are deleted. The Autoimmune 
Regulator gene (AIRE) is thought to be crucial in the process 
of negative selection by controlling the expression of tissue 
specific antigens in the thymic medullary epithelial cells. 
Although this is a simplistic explanation of the role of the 
thymus in TCL development, this model of clonal selection 
holds true and serves to illustrate some of the current 
theories on the association of thymomas and autoimmune 
disease and secondary neoplasms. It is important to note 
that patients with thymomas have immature TCL’s in the 
periphery that are thought to originate from the tumor itself. 
Also, in over 90% of thymomas the neoplastic cells do not 
express AIRE. There are different theories on the etiology of 
the immune disturbances in patients with thymoma. The 
current theories are not mutually exclusive.  
 
a. Immature T-cell theory Thymocytes derived from 
thymomas may be immature, which is supported by 
expression of antigens such as TdT+, T6+, T4+, and T8+, 
which are markers of TCL immaturity. Immature thymocytes 
lack the important negative clonal selection in the thymic 
medulla where self-tolerance is induced. Those immature 
TCL’s are released to the periphery and become 
autoreactive. The higher incidence of immune disorders in 
patients with WHO type B thymoma that are thought to 
originate from the cortical thymic epithelial cells appear to 
partially support this theory.  
 
b. Neoplastic-genetic theory Antigen specificity is acquired in 
the thymic cortex causing a rearrangement of T-cell receptor 
genes. In thymomas, the neoplastic cortical cells are rapidly 
dividing, increasing the chances of genetic mutations. 
Neoplastic thymic epithelial cells in thymomas are genetically 
different from normal thymic epithelial cells and often present 
with impaired expression of HLA-DR. This affects positive 
cortical selection and may be a factor in auto reactivity to 
HLA-B8 and HLA-A24, both significant predictive factors for 
myasthenia gravis.  
 
c. Combined cellular and humoral theory This theory links 
the cellular and humoral arms of the immune system. The 
first step is the release of a large number of thymoma 
derived CD8 TCL’s with impaired self-tolerance, initiating the 
autoimmune process. CD4 TCL’s are then activated, which 
in turn activate B cells to produce autoimmune antibodies. 
The presence of autoantibodies in patients with thymoma 
and a range of autoimmune diseases support this theory. 
Also, this theory explains the immunodeficient syndromes in 
patients with thymoma, believed to be caused by 
autoantibodies directed towards cytokines such as interferon 
gamma, interferon alpha, IL-22, IL-17, and IL-12.  
 
All three theories are attractive and it is quite possible that all 
three mechanisms interact in patients with thymoma. 
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However, all three theories are centered on the released of 
abnormal or immature TCL to the periphery by the thymoma. 
This may not explain our finding of increased incidence of 
extrathymic cancers prior to the diagnosis of thymoma. 
Some of the patients in our study had an extrathymic cancer 
diagnosed over 5 years prior to the diagnosis of thymoma, 
and the incidence of extrathymic cancers prior to the 
diagnosis of thymoma was 8 times that of the age matched 
general population. We have been working with an 
alternative theory that may explain the higher incidence of 
cancers prior to the diagnosis of thymoma. We hypothesize 
that the disturbance in TCL’s “education” originates in the 
non-neoplastic thymic epithelial cells, which may explain the 
immune deficiency prior to the diagnosis of thymoma. We 
also hypothesize that the thymoma may be a marker of an 
already disturbed thymic epithelial cell. In summary, 
thymomas are closely linked to immune phenomena such as 
autoimmune diseases, immunodeficiency, and increased 
incidence of secondary cancers. It is hard to explain all 
syndromes with current theories and it is quite likely that 
more than one theory plays a role in each case. More studies 
are needed to properly clarify the role of the thymic epithelial 
cell and thymoma in the immune syndromes associated with 
thymoma.  
 
 
GENERAL SESSION II: THYMUS AND THE IMMUNE SYSTEM 
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GS2.2: THYMOMA, ANTICYTOKINE AUTOANTIBODIES, 
AND IMMUNODEFICIENCY 
 
Sarah Browne  
Laboratory of Clinical Infectious Diseases NIAID, NIH, 
Bethesda/UNITED STATES OF AMERICA 
 
The importance of anticytokine autoantibodies in disease 
pathogenesis is being increasingly appreciated with 
examples including pure red-cell aplasia due to anti-
erythropoietin autoantibodies, pulmonary alveolar proteinosis 
due to anti-GM-CSF autoantibodies and adult onset 
immunodeficiency due to anti-interferon-gamma 
autoantibodies. Patients with thymic malignancy have high 
rates of autoimmunity leading to a variety of autoimmune 
diseases, most commonly myasthenia gravis caused by anti-
acetylcholine receptor autoantibodies. High rates of 
autoantibodies to cytokines have also been described, 
particularly in the context of opportunistic infection, although 
their specific contribution to the development of 
autoimmunity or immunodeficiency remains to be quantified. 
Interestingly, many patients also show aberrancies in B and 
T cell subsets, further complicating whether the basis of their 
immunological dysfunction is humoral, cellular or both. 
Further investigation into the relationship between 
anticytokine autoantibodies and thymoma may shed light on 
the immunological complications seen frequently in thymoma 
as well as inform us about underlying mechanisms of 
autoimmunity and anticytokine autoantibody production in 
general. 
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Cross-talk between mature single positive (SP) thymocytes 
and thymic medullary epithelial cells (mTEC) is critical for 
thymic development and maintenance of self tolerance. We 
have analyzed the role of CD28-CD80/86 and CD40-CD40L 
costimulatory interactions, which are mediators of negative 
selection and self tolerance, on mTEC development. We find 
that these costimulatory pathways are critical for medullary 
development and that their function involves regulation of 
LTa, LTb and RANK expression. To probe the mechanism 
underlying the requirement for SP thymocytes in medullary 
development, we assessed the effect of selective deletion in 
TEC of TRAF3, an inhibitor of non-classical NF-kB signaling. 
We find that TEC-specific deletion of Traf3 sustains RelB-
dependent mTEC development in the absence of CD40 and 
LTbR, or in the complete absence of TCRab SP thymocytes. 
In contrast, deletion of TRAF3 failed to reverse mTEC 
deficiency in the absence of RANKL, consistent with a 
necessary role of RANKL expressed on cells other than SP 
thymocytes. These findings demonstrate a striking link 
between costimulatory requirements for negative selection of 
self-reactive T cells and the requirement of these same 
CD28 and CD40L costimulatory pathways for development 
of the medullary compartment in which negative selection 
occurs. We further find that signaling by costimulatory 
molecules expressed by SP T cells is needed to overcome 
TRAF3-imposed arrest in mTEC development mediated by 
inhibition of non-classical NF-kB. We conclude that TRAF3 
imposes requirements for SP T cells and costimulation-
mediated crosstalk in generation of the medullary 
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compartment in which costimulus-dependent tolerization 
occurs. 
 
Keywords: thymus, crosstalk, NFkB 
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GS3.1: PRECLINICAL MODELS FOR THYMIC TUMORS 
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Department Of Pathology & Laboratory Medicine, Indiana 
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STATES OF AMERICA 
 
Preclinical models have been important tools to understand 
the molecular pathology of human cancers and to develop 
better therapeutics. Various human cancer cell lines isolated 
from patient tumors have provided extensive information for 
the cellular and molecular mechanisms of cancer biology. 
Additionally, recent improvements in genomic technologies 
are providing rational therapeutic strategies targeting distinct 
pathways. The successful translation of such targeted drugs 
to clinical application depends on effective preclinical proof of 
concept models in relevant cancers. Recapitulating the 
underlying genetics, these models may offer distinct 
advantages in the preclinical testing of potential therapies. 
However, this has not been the case for thymic 
malignancies. New treatments are based on the studies 
extrapolated from other epithelial tumors. Targeted 
therapeutic strategies are not available due to the rarity and 
complexity of the disease and lack of relevant in vitro and in 
vivo models. In this presentation, I will be discussing the 
established preclinical models involving current in vivo and in 
vitro models and their utility relevant to thymic malignancies. 
In vitro models Among the four human cell lines reported to 
date, three were isolated from thymic carcinoma patients (1-
3), while one cell line was established from type B1 thymoma 
(3). We recently have established and characterized a novel 
thymoma cell line (IU-TAB-1), which was derived from a 
patient with the stage II thymoma (WHO-type AB tumor)(4). 
Histological and FACS analyses confirmed the thymic 
epithelial (TE) nature of this cell line by the presence of 
epithelial cell markers (pan-cytokeratin and EpCAM/CD326), 
the presence of cell surface markers of TE cells and nuclear 
p63 and by the absence of lymphoid and other leukocyte and 
T-cell markers. Unlike the indolent behavior of IU-TAB-1, the 
thymic carcinoma cell line established by Ehemann et al. 
was derived from a poorly differentiated thymic carcinoma 
(Stage III) and exhibits a high proliferation index. In vivo 
models We have further developed an in vivo model (IU-
TAB-1/NOD/SCID xenograft model) forming ectopic tumors 
that reached a volume of 1000 mm3 at around 130 days 
when in Matrigel-plugs, and around 148 days when 
implanted alone (4). Importantly, the kinetics of tumor 
development is consistent with the indolent nature of AB 
thymomas. We also determined the tumorigenicity of the 
thymic carcinoma cell line (kind gift of Dr. Rieker, Heidelberg, 
Germany) in NOD/SCID xenograft model and demonstrated 
that the thymic carcinoma cells form tumors that reached a 
volume of 1000 mm3 at around 45 days when in Matrigel-
plugs, confirming that they grow faster than IU-TAB-1 
xenograft model. The use of these xenograft models will 
permit studies of target validation and pre-clinical 
assessment of targeted therapeutics in this cancer. Our 
group has also developed an animal model (Thymoma 
insertional mutation; Tim-1), which spontaneously develop 
thymomas at a very high penetrance due to the transgene 
insertional mutagenesis into F2-G region of mouse 
chromosome 2 (5). Tumor progression leads to obstruction 
of the great vessels and death from cardiac failure. Disease 
is more aggressive in females than in males (at 20 weeks, 
approx. 75% versus 42% mortality, respectively). 
Translocation at the syntenic region in humans has been 
associated with thymomas (6). Cell lines have also been 
derived from thymic epithelial tumors developed in Tim-1 
mice, designated as TVT cell lines, and possess the 
morphology and properties of cancer epithelial cells. Since 
the development of tumors in Tim-1 mice is variable and the 
mice can die early due to cardiovascular complications, we 
are in the process to develop a Tim-1 mouse derived 
syngeneic mouse model that will be useful for future 
preclinical drug screening in thymomas. Development of 
patient-derived tumor xenografts (PDX) is the next logical 
step, since these can provide a better understanding of the 
disease’s biology. Utility of preclinical models relevant to 
thymic malignancies These preclinical models can be 
utilized to validate the functional aspect of the novel 
molecular targets as well as to evaluate novel therapeutic 
agents in thymic malignancies. Development of knock-in and 
knock-down of the genes associated with metastatic gene 
signature of thymoma (7) and thymic carcinoma (8) will help 
to understand the unique biology of thymic tumors on their 
path of progression and metastasis. Interestingly, the IU-
TAB-1 cells are not metastatic and exhibit very low 
expression levels of genes upregulated in gene signature 
that determines metastatic behavior of thymomas, while 
thymic carcinoma cell line expresses genes that are 
upregulated in metastatic phenotype. Besides genetic 
manipulations, these models are necessary to evaluate both 
in vitro and in vivo efficacy of therapeutic agents as well as 
understanding the molecular basis of these agents found to 
have some efficacy in patients with thymic tumors. For 
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example, octreotide, a somatostatin analogue, with known 
activity in thymomas, can now be compared with next 
generation analogues such as pasireotide. Our gene 
expression studies have suggested that PDGFR pathway is 
significantly associated with metastatic phenotype in both 
thymoma and thymic carcinoma. Our initial efforts focused 
on the in vitro efficacy of dovitinib alone, a tyrosine kinase 
inhibitor targeting PDGFR and FGFR, and in combinatorial 
setting with vorinostat (SAHA), a member of a larger class of 
compounds that inhibit histone deacetylases (HDAC). Using 
MTT assay, IC50 values of dovitinib, the concentrations that 
inhibit 50% of cell survival, were similar for IU-TAB-1 (12 μM) 
and thymic carcinoma cell line (11 μM). No additive effect of 
SAHA on dovitinib was observed in both cell lines. Further 
studies are ongoing. In conclusion, these preclinical models 
will provide excellent tools to study the relevance and 
functional role of novel therapeutic agents as well as the 
rationale for combination therapies, and provide insight for 
the future treatment strategies of patients with these rare 
malignancies.  
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Epithelial tumors of the thymic gland are classified as 
thymomas and thymic carcinomas based on presence of 
cytologic atypia. Thymic carcinomas are aggressive 
neoplasms associated with early recurrence, metastasis and 
often death. In contrast, thymomas are indolent and are 
relatively infrequent associated with recurrences or 
metastases. However, recent data including ours suggest 
that all types of thymomas, albeit with different frequencies, 
can give rise to metastases. The rarity of the tumors and the 
indolent behavior of thymomas have led to significant poor 
understanding of biologic behavior of these tumors. The 
prognosis of thymomas is based on the following 3 factors: 
Histologic type, Tumor stage, and the presence of residual 
disease of the surgery. The histological classification has 
been controversial.In the WHO working schema, spindle cell 
thymomas were classified as type A with the additional 
designation of AB for tumors which are lymphocyte-rich. 
Tumor is composed of polyclonal cells were classified as of 
B type with further sub-classification B1 to B3 based on the 
amount of epithelial cellularity and lymphocyte content. The 
WHO classification clearly stated that types A, AB and B1 
are benign. Recent undertaken by our group in addition to 
others as clearly demonstrated that thymomas of all 
histological types give rise to metastatic tumors. The 
classification can in practice be quite difficult to apply. A 
recent study analyzed the concordance of 17 thoracic 
pathologists for classifying 95 cases of thymomas1. The 
overall level of agreement was moderate (kappa 0.45) with 
significant improvement (kappa 0.63) when cases were 
classified in two groups (A+AB+B1 and B2+B3+C). Tumor 
stage is typically determined using the Masaoka staging 
system. Tumors that are localized with minimally invasion of 
the surrounding structures have a better prognosis than 
those associated with invasion of pleura, pericardium and or 
great vessels. Patients without residual disease have a 
worse prognosis than those without any residual disease. 
The utility is operator dependent and to significant extent 
dependent on grossly visible disease. In order to progress 
beyond subjective morphological classification or 
intraoperative assessment of extent of disease, it is 
necessary to develop an objective method of accessing the 
prognosis of thymomas. As a first step in this direction, we 
analyzed the gene expression in a series of 36 thymomas2. 
The analysis of the gene expression study showed that 
clustering based on gene expression analysis correlated to 
some extent with histologic classification (P=<0.05). 
However none of the molecular clusters were histologically 
pure as there was a crossover of different histologies within 
each cluster. There was no correlation of histology with stage 
and metastasis. We further analyzed the correlation of gene 
expression with tumor stage and development of metastasis. 
Predictive analysis of microarray (PAM) identified 9 genes-
based algorithm was associated with tumor stage. Similarly, 
a combination of 10 genes could identify cases associated 
with metastasis with a high degree of certainty. In order to 
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validate this data on qRT-PCR platform validation was 
performed on 75 cases3. This data initially showed that all 
the 19 genes together could reliably predict the outcomes of 
thymomas. The signature was further refined to include only 
the 9 of the 10 metastasis associated genes. The signature 
was independent of traditional prognostic factors such as 
tumor size, stage, histology type and extent of residual 
disease. Further plans include an independent validation of 
the gene signature in other well annotated cohorts as well as 
prospective evaluation in clinical trial. It is also important to 
note that the genes constituting the genes signature are not 
related to proliferation but have distinct well described roles 
in other cancers. Identification for prognostic signature in 
thymomas raises two important questions. 1) Would the 
signature have utility in thymic carcinomas? and 2) Given the 
difficulties inconsistently classifying thymomas and 
distinguishing them from thymic carcinomas, could the 
signature reliably separate these two entities? The 
expression of all 19 genes was analyzed in a relatively large 
series of thymic carcinomas (n=38). This analysis showed 
two important findings 1) the 9-gene signature is specific for 
thymomas and loses its predictive abilities in patients with 
thymic carcinomas. 2) A subsequent analysis showed that 
the outcomes of patients with thymic carcinomas can be 
predicted using a subset of 10 genes (from the 19 genes). 
These genes are distinct from those in the thymoma 
signature consistent with the biologic difference between the 
two entities. Given to the relatively small number of cases, 
we consider this analysis “hypothesis generating” result that 
needs further confirmation in additional cohorts of patients 
with thymic carcinoma. The rarity of thymic carcinomas is 
making it difficult to identify cohorts with well annotated 
follow-up information. The histologic distinction between 
thymomas and thymic carcinomas can be on many 
occasions quite difficult. The presence or absence of 
cytologic atypia is a subjective distinction. More specifically, 
the distinction of B3 thymomas with focal atypia from thymic 
carcinomas can be quite difficult. In addition, cytological 
atypia has now been described even in spindle cell 
thymomas. In a recent paper, Nonaka and Rosai describe a 
series of cases of spindle cell thymomas with significant 
cytological atypia and mitotic activity4. In view of these 
difficulties, we explored the possibility of using gene 
expression to distinguish the two entities. The data from this 
study is being presented at the 2013 ITMIG meeting 
(Gökmen-Polar et al). In brief, a 12 gene signature can 
accurately distinguish thymomas from thymic carcinomas 
(p<0.001). In summary, gene expression analyses have 
identified clear distinction between thymomas and thymic 
carcinomas. Within thymomas, we have described and 
validated 9-gene signature for prognostication; the signature 
is an independent prognostic factor. In a more exploratory 
analysis, we have further identified a signature that 
distinguishes thymic carcinomas a poor prognosis from those 
with relatively good prognosis. It must be noted that the 
signature of thymic carcinomas requires further validation.  
 
References:  
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Background: Thymomas are one of the most rarely 
diagnosed malignancies. The challenge of histological 
subtyping of these tumors along with an inadequate 
understanding of the transcriptional biology is a hindrance to 
the development of prescriptive targeted therapies. Next-
generation RNA sequencing enables a comprehensive and 
quantitative measurement of the entire transcriptome. Taking 
advantage of this technology, we performed comprehensive 
next-generation RNA sequencing on a set of thymomas to 
examine the transcriptional landscape of this disease and to 
identify novel molecular hallmarks which can lead to more 
precise therapeutic interventions.  
 
Methods: RNA was sequenced from 13 thymic malignancies 
and 3 normal tissues obtained from the Indiana University 
Simon Cancer Center using a Life Technologies SOLiD 
sequencer. The WHO subtypes of our samples were 
evaluated by a single pathologist blinded to the outcomes of 
the sequencing and include: (4) type A, (2) AB, (1) B2, (5) 
B3, (1) C, and (3) normal tissues. For gene expression, 
reads were mapped to the human genome (hg19) using the 
LifeScope software with outputs imported into Partek 
Genomics Suite for statistical analyses and subsequent 
pathway analyses was performed using IPA 9.0 (Ingenuity 
Systems). Validation of microRNA expression was performed 
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using an additional set of 35 thymomas and a custom 
TaqMan Low Density Array (Life Technologies). For protein 
measurements, we used pre-made enzyme-linked 
immunosorbent assays (ELISAs) for PTEN, phospho-AKT 
(Ser-473), and Beta-Actin (Cell Signaling Technology).For 
cell based studies, a thymoma cell line (IU-TAB1) was used 
and cells were treated with a panel of PI3K pathway 
inhibitors currently in clinical trial (BEZ235, BKM120, CAL-
101, GDC-0980, GDC-0941, MK-2206, PF-04691502, XL-
147). Cell viability was assessed using the Promega 
CellTiter-Flour assay, with statistical analysis using Prism 
Graphpad.  
 
Results: Unsupervised hierarchical clustering of gene 
expression values revealed 100% concordance between 
gene expression clusters and WHO subtype. A subsequent 
unsupervised clustering of 705 precursor-microRNAs also 
showed substantial concordance between clusters and 
subtype. By analyzing the dendrograms, A & AB tumors 
were significantly different from other thymomas. Using 
differential expression analysis, a substantial differentiator 
was a large microRNA cluster on chr19q13.42 that is 
significantly over-expressed in all A & AB tumors and whose 
expression is virtually absent in the others thymomas. Over-
expression of this microRNA cluster, which is normally silent 
in adult tissues, has been documented to result in 
hyperactivated PI3K/AKT Pathway by down-regulating 
PTEN. This was confirmed at the RNA level using pathway 
analysis revealing over-expression of PI3K-p110, PREX2, 
and down-regulation of FOXO in A & AB tumors. To confirm 
the activation of the PI3K/AKT pathway at the protein level, 
we used ELISAs on protein lysate from our validation cohort 
and observed significant down-regulation of PTEN, and up-
regulation of phospho-AKT (Ser473) in the tissues that were 
positive for the chromosome 19 microRNA cluster. Lastly, 
treatment of IU-TAB1 thymoma cells with a panel of 
PI3K/AKT/mTOR inhibitors resulted in marked reduction of 
cell viability suggesting sensitivity to these agents.  
 
Conclusions: Next-generation RNA sequencing showed 
concordance with the WHO thymoma histologic classification 
and support the notion that AB thymomas are a variant of 
type A thymomas. Furthermore, the expression of a large 
microRNA cluster on chr19q13.42 which affects the activity 
of PI3K pathway is over-expressed only in type A & AB 
thymomas, suggesting the possible exploration of PI3K 
inhibitors in patients with these subtypes of tumor. 
 
Keywords: RNA-seq, microRNA, thymoma, Next-
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The complexities of cancer research, especially in rare 
tumors are substantial. The normative format for most 
traditional clinical research is the conduct of prospective 
randomized trials which are not possible in a disease like 
thymic malignancies where fewer than 750 cases are 
diagnosed annually in the United States. The Cancer Care 
Engineering (CCE) project is a knowledge acquisition 
framework that integrates clinical observations, patient 
outcomes and translational research so as to improve 
treatment outcomes. CCE began with collaboration between 
a transdisciplinary team (basic scientists, engineers, 
physicians) from Purdue University and the IUSCC who 
focused on a common malignancy, colorectal cancer. The 
challenge was optimizing information management and 
exchange of clinical information with multi-laboratory analysis 
of serum and colonic tissue obtained from patient volunteers 
undergoing routine colonoscopy. The CCE Hub emerged as 
a unique tool to address these issues. The Hub data base 
technology provided an opportunity to expand its capability 
through efforts with the International Thymic Malignancies 
Interest Group (ITMIG). The challenge was how to perform a 
global data collection of information of a rare tumor. Together 
with an ITMIG Working Group, an “essential dataset” 
spreadsheet was developed. A sophisticated portal was 
implemented to 1) authenticate contributing hospitals, 2) 
audit spreadsheets for format & content inconsistencies in 
addition to other data cleaning, 3) update database with 
cleaned or augmented hospital data, and 4) generate patient 
de-identified versions of the data to be used for staging 
analysis by CRAB[1]. We designed and implemented online 
searchable “data views” (updated in real time) to explore, 
search, graph and download – both for restricted hospital 
viewing and for full database exploration by CRAB from the 
cceHUB ITMIG portal. Data contributions on a retrospective 
database began in October, 2012 and as of January, 2103 
over 8000 cases have been entered through the cceHUB 
ITMIG portal. Data has been contributed by hospitals in 
Turkey, Korea, China, Japan, UK, Thailand, Italy, Germany, 
Belgium, Netherlands, Argentina, Spain, France, Romania, 
Denmark, Greece, and the USA. In January, 2013 a 
prospective database was launched that has dataview 
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technology, with a customized, event-based workflow to 
capture detailed, comprehensive patient data by episode for 
initial presentation, imaging, pathology, surgery, treatment, 
staging and follow-up. Ongoing collected data will be used 
for research projects approved by ITMIG. 
(Special acknowledgements to Drs. Ann Christine Catlin and 
Joseph F. Pekny from Purdue University)  
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The use of modern radiation techniques with the goal of 
avoiding toxicity is particularly important in patients who have 
high expected long-term survival rates such as patients with 
thymic malignancies. Radiation techniques have markedly 
evolved over the past 2 decades from two-dimensional 
treatments to three-dimensional conformal radiation therapy 
(3D-CRT) and even more conformal intensity-modulated 
radiation therapy (IMRT) techniques. Furthermore, proton 
therapy may provide further advantages in sparing normal 
tissue, and is currently under investigation for thoracic 
malignancies including thymomas. The availability of on-
board image guidance that allows patient imaging on the 
treatment table has improved our ability to more closely 
guide and monitor the treatment. Some of these techniques, 
in particular IMRT, have expanded the technical capabilities 
of targeting complex shapes, e.g. pleural implants in stage 
IVA thymomas, while sparing adjacent lungs or heart tissue. 
The evolution of these radiation treatment techniques has 
allowed greater sparing of normal organs at risk and led to a 
decreased risk for short- and long-term toxicities, as 
illustrated in many organ sites. Accurate target delineation is 
increasingly critical when highly conformal radiation therapy 
techniques are used in order to avoid marginal recurrences. 
Target delineation based on a dedicated treatment-planning 
CT scan involves the delineation of the gross tumor volume 
(GTV) in unresectable thymomas or the clinical target 
volume (CTV) as a surrogate of microscopic residual disease 
in postoperative thymoma patients. More recently, 4D 
planning CT scans can be obtained at the time of treatment 
planning that allow assessment of target motion throughout 
the respiratory cycle. This leads to an expansion of the 
GTV/CTV to an internal target volume (ITV). Finally, the ITV 
is expanded to the planning target volume (PTV), which 
takes any patient positioning uncertainty and variability into 
account and represents the volume that the radiation 
treatment is prescribed to. Modern imaging techniques 
including PET-CT and MRI may aid in even more accurate 
target delineation in the future. Radiation oncologists are 
encouraged to follow the definitions and reporting guidelines 
for the design of radiation therapy fields, as published by 
ITMIG. The short- and long-term toxicities of radiation 
therapy are tightly correlated to the volume that was 
irradiated, the radiation dose per fraction, and the total 
radiation dose, as well as the age of the patient and the time 
interval from the end of radiation therapy. The increased 
conformality of modern radiation techniques allows 
unprecedented sparing of normal organs at risk, such as the 
lungs, the esophagus, the heart, the brachial plexus, and the 
spinal cord. There has been a noticeable decrease in acute 
side effects with decreased radiation doses to these normal 
tissues. Given the location of most thymic tumors in the 
anterior mediastinum, superior to the heart, as well as the 
use of typically moderate radiation doses in the range of 50-
60 Gy, acute toxicities from irradiation of thymoma patients 
are generally mild. The long life expectancy of most patients 
with thymoma, however, puts them at risk for long-term 
toxicities, such as coronary artery disease, lung fibrosis, 
esophageal stenosis, and secondary malignancies. While 
reports on the toxicity from radiation therapy specifically for 
thymomas are largely anecdotal, it is reasonable to draw 
conclusions on normal tissue tolerances and long-term 
toxicities observed in patients who underwent radiation 
therapy for other indications, such as lymphoma, breast 
cancer, and pediatric cancers. Avoidance of additional risk 
factors for long-term toxicities are a critical component of the 
follow-up care of long-term survivors and should include 
smoking cessation, management of hypercholesterolemia 
and hypertension, and routine screening for early detection 
of secondary malignancies when indicated. 
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The indications for postoperative radiation therapy in the 
setting of locally advanced thymic malignancies have not 
been well established. Due to the rarity of the disease, data 
is primarily limited to small retrospective studies, often from a 
single institution. As a result, outcomes have varied between 
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reports, with some analyses demonstrating control rates of 
greater than 90%, and others with higher rates of 
progression. In light of this conflicting data, as well as 
because no randomized prospective studies have been 
performed to answer this question, recommendations 
regarding the utility of postoperative radiation therapy in the 
context of resected stage II-III invasive thymoma or thymic 
carcinoma are mixed. To attempt to provide strong data on 
this topic, ITMIG has recently initiated the design of a 
prospective phase III randomized trial in which patients with 
completely resected locally advanced thymic malignancies 
are randomized to postoperative radiation therapy or 
observation, with the primary endpoint being overall survival. 
This presentation will focus on the conflicting data examining 
the efficacy of postoperative radiation in the setting of 
completely resected thymoma in terms of improving 
locoregional control and survival, as well as the rationale and 
design of ITMIG’s proposed randomized phase III study, 
currently in development through the Eastern Cooperative 
Oncology Group (ECOG). 
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Thymic epithelial neoplasms are divided into thymomas and 
thymic carcinomas. Thymomas are epithelial tumors that 
have retained the organo typical features (well-developed 
lobular architecture, presence of a dual cell population of 
neoplastic thymic epithelial cells and lymphocytes, dilated 
perivascular spaces, areas of medullary differentiation, lack 
of cytologic features of malignancy of neoplastic thymic 
epithelial cells) of the thymic gland. On the other hand, 
thymic carcinomas are overtly malignant epithelial tumors 
showing cytologic atypia, invasive margins, and loss of an 
organo-typical appearance. It is important to clarify that 
thymoma does not represent the “benign” counterpart of 
thymic carcinoma, but rather exhibits at least low-grade 
malignant behavior with the potential for invasion and 
metastasis. Thymic carcinoma represents a heterogeneous 
group of tumors with a wide morphologic spectrum. Only 
rarely have larger series of thymic carcinoma been reported 
in the literature, and these have often included material 
derived from small biopsy specimens. In addition, many of 
the studies included neuroendocrine carcinomas or salivary 
gland–type thymic tumors, which show different 
clinicopathologic features and outcome altogether Although 
the predominant approach in the treatment of thymoma and 
thymic carcinoma is surgery, radiation therapy also has an 
important role, either as postoperative therapy to reduce the 
risk of mediastinal recurrence or as part of definitive 
treatment for patients that who cannot undergo surgery. We 
present here a review of radiation therapy for thymic 
malignancies and briefly discuss the potential benefits from 
novel technologies for such treatment. Thymic carcinoma is 
a rare but more aggressive tumor which has a tendency to 
fail locally and distantly. Thymic carcinoma has more 
frequent EGFR and/or HER2 abnormalities compared to 
thymoma., and the outcome of thymic carcinoma is usually 
worse than invasive thymoma. Induction Chemotherapy or 
Molecular Targeted Agents: For thymic carcinoma and 
invasive thymoma, our traditional chemotherapy regimens 
are cyclophosphamide, adriamycin, cisplatin and prednisone 
x3 cycles followed by surgery. However more recently thymic 
carcinoma has been treated as lung cancer. We need to 
check histology squamous carcinoma, neuroendocrine 
carcinoma, small cell carcinoma or adenocarcinoma as well 
as EGFR mutation, K-ras, and ALK mutation. If the thymic 
carcinoma demonstrates targetable mutation, those patients 
need to be treated EGFR-TKI, crizotinib etc. Postoperative 
Radiation Therapy: Indications R0 (Completely 
Resected) Thymic Malignancies In general, radiation 
should be considered more strongly as the risk of recurrence 
increases. Therefore, for patients with the lowest likelihood of 
recurrence (i.e. completely resected Masaoka stage I 
thymoma), radiation can be safely omitted. For those at 
intermediate risk of local recurrence after complete resection, 
i.e. those with aggressive tumor histologies (such as thymic 
carcinoma) or Masaoka stage II and stage III disease, 
retrospective evidence exists both to support and contradict 
claims of benefit from adjuvant radiotherapy after complete 
resection. In general, our institutional practice includes 
postoperative radiation for completely resected Masaoka-
Koga stage III thymoma and stage II or III thymic carcinoma. 
Risk assessment and stratification is usually done in a 
multidisciplinary setting and drives the choice of adjuvant 
treatment. The International Thymic Malignancy Interest 
Group (ITMIG) published a set of definitions and reporting 
guidelines for the use of radiation therapy for thymic 
malignancies in 2011. Pertinent recommendations for 
postoperative therapy are as follows. First, the term 
“postoperative” should be used for situations in which the 
tumor is resected and no residual disease is evident on 
Copyright © 2013 by the International Association for the Study of Lung Cancer 14

imaging. If gross disease is present on postoperative 
imaging, then the disease should be defined as “recurrent” 
and the intent as “radiation for postoperative disease.” 
Second, the minimum acceptable dose for postoperative R0 
disease is 50 Gy in 5 weeks. Finally, radiation to elective 
nodal regions not recommended, and the extent of 
malignancy before surgery should be used as a guide for 
designing the treatment fields. Microscopic Positive 
Margins (R1) and Gross Disease (R2) Radiation for R1 or 
R2 thymic malignancies should be started within 3 months of 
surgical resection. Doses between 40 Gy and 64 Gy are 
most appropriate for microscopically positive margins, 
whereas doses of 54 Gy or higher should be used for gross 
disease; both given in standard fractions of 1.8- to 2.0-Gy. 
Patients with positive margins should be considered for 
concurrent chemotherapy and radiotherapy, especially 
among patients with thymic carcinoma. Definitive Radiation 
Therapy Definitive radiation therapy is generally used for 
patients who are not candidates for surgery because of 
either the extent of disease at diagnosis or medical 
comorbidities. Because chemotherapy is a known radiation 
sensitizer, the combination of chemotherapy and radiation is 
considered most likely to control disease in these 
circumstances. In this setting, which is analogous to 
recurrent disease after surgical resection, we recommend 
radiation doses of 60 Gy -66 Gy to encompass gross disease 
plus a margin for microscopic regions at risk. Thymic 
carcinoma behaves more like non-small cell lung cancer 
arising from the thymus. Therefore, unresectable thymic 
carcinoma needs to be treated based on the histology or 
molecular biomarkers of expression e.g. EGFR, HER2 c-KIT 
and BCL-2. Approximately 50% of thymic carcinoma has 
squamous histology which can be treated with cisplatin 
based chemotherapy and radiotherapy. If unresectable 
thymic carcinoma has atypical carcinoid histology or small 
cell carcinoma arising from the thymus, etoposide and 
cisplatin plus radiotherapy might be the best option. For 
recurrent thymic carcinoma, molecular targeted agents e.g 
EGFR-TKI, c-KIT inhibitors and VEGFR inhibitors can be 
delivered in the protocol setting with or without radiotherapy.  
In conclusion, thymic carcinoma needs to be treated almost 
as lung cancer arising from the thymus. We need to 
individualize induction chemotherapy for resectable thymic 
carcinoma based on histology or molecular targeted agents 
based on EGFR mutation, K-Ras, mutation or ALK mutation, 
HER2-neu positivity or amplification or c-KIT and BCL-2 
mutation. For unresectable thymic carcinoma such as small 
cell carcinoma arising from the thymus needs appropriate 
radiosensitzing chemotherapy or molecular targetable agent 
and radiotherapy would be recommend. The use of 
advanced radiation therapy technologies to minimize the 
dose to mediastinal structures for patients with thymic 
carcinoma is critical to reduce cardiac or lung toxicity 
especially long term survivors.  
Keywords: thymic, indivisualized, management, Carcinoma 
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Background: The relationship between thymoma and 
myasthenia gravis (MG) is well known. We investigated the 
detailed clinical characteristics of patients who had 
undergone resection of both thymoma and MG. 
 
Methods: We registered patients with thymic epithelial tumor 
who had undergone resection between 1991 and 2010 at 29 
institutes participating in Japanese Association for Research 
of Thymus (JART). 
 
Results: The total number of registered cases was 3033. Of 
them, 3000 were eligible for the study. MG was found in 667 
patients (22.3%) with stage I thymoma (n=262, 39.2%), 256 
with Stage II (38.3%), 84 with Stage III (12.6%), 45 with 
Stage IVa (6.7%), and 18 with Stage IVb (2.7%). Earlier 
stage of the thymoma was more frequently observed in 
patients with MG than those without MG (p = 0.00036). 
Cases of MG were found in 12.5% of patients with type A 
thymoma, 14.9% with type AB, 23.8% with type B1, 40.3% 
with Type B2, 25.5% with Type B3, and 1.1% with thymic 
carcinoma, respectively. Patients with type B thymoma had 
more frequent involvement of MG (P<0.0001). The number 
of patients with MGFA class I, II, III, IV, and V was 191 
(28.6%), 298 (44.6%), 98 (14.7%), 8 (1.2%), and 10 (1.4%), 
respectively. Average serum titer of anti-acetylcholine 
receptor antibody (AchRAb) of the patients with MGFA class 
I, II, III, IV, and V was 23.8, 58.4, 79.6, 46.8, and 43.1 
nmol/L, respectively. Severity of MG correlated with MGFA 
classification in patients with thymoma. AchRAb was positive 
in 99.3% of patients with thymoma and MG. On the other 
hand, AchRAb was positive in 22.4% of patients with 
thymoma but without MG preoperatively. During the 
postoperative follow up, 60 patients with MG (9.0%) and 368 
without MG (15.8%) experienced thymoma recurrence. 
Forty-three patients with both thymoma and MG died due to 
thymoma (n = 10), MG (n = 7), other malignancy (n = 9), or 
other disease (n = 17). The overall postoperative survival 
rate of patients with thymoma and MG was not significantly 
different from that of the patients without MG (figure).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion: Our database, with records of 3000 patients 
with thymic epithelial tumor, showed that a 22% of patients 
with thymic epithelial tumor were complicated by MG. 
Patients with WHO type B thymoma had more frequent 
involvement of MG. Almost all of the patients with both 
thymoma and MG had positive AchRAb, and 22.4% of 
thymoma patients without MG had positive AchRAb. In MG 
patients with thymoma, AchRAb correlated with MG severity. 
MG had no impact on the overall survival of patients with 
thymic epithelial tumor. 
 
Keywords: thymoma, myasthenia gravis, anti-acetylcholine 
receptor antibody, multiinstitutional study 
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Chiappetta1, Valentina Dall'Armi2, Dania Nachira1, 
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Background: Thymectomy plays an important role in 
patients with myasthenia gravis. This study aims to explore 
predictors of postoperative myasthenic crisis after 
thymectomy and to define a predictive score of respiratory 
failure. 
 
Methods: From 01/1995 to 12/2011, the clinical data of 177 
patients with myasthenia gravis who underwent thymectomy 
were retrospectively reviewed. The following factors were 
analyzed in relation to the occurrence of myasthenic crisis: 
gender, age, BMI, anti-AchR-antibody level, bulbar 
symptoms, comorbidities, duration of symptoms, Osserman-
stage, MGFA, history of myasthenic crisis, use of 
immoglobulins or plasmapheresis, kind of medical therapy, 
spirometric and blood gas parameters, histolgy, kind of 
surgery, non-myasthenic complications, duration of 
intubation. 
 
Results: Twenty-two patients experienced postoperative 
respiratory failure after thymectomy. Univariate analysis 
revealed a correlation with age higher than 60 years 
(p=0,040), Osserman-stage (2B, p=0,037; 3-4, p=0,015), 
bulbar symptoms (p=0,008), BMI higher than 28 (p=0,003), 
preoperative plasmapheresis (p=0,021), duration of 
symptoms higher than 2 years (p=0,036), invasive surgery 
(p=0,045), lung (p=0,008), pericardial (p=0,006) or pleural 
resection (p=0,012), VC% lower than 80% (p=0,025), PaCO2 
higher than 40 mmHg (p=0,032). Multivariate logistic 
regression analysis showed that Osserman stage (2B, 
p=0,039; 3-4, p=0,013), BMI higher than 28 (p=0,035), 
history of myasthenic crisis (p=0,007), duration of symptoms 
higher than 2 years (p=0,036), lung resection (p=0,002) 
independently predict postoperative myasthenic crisis. 
Excluding history of preoperative myasthenic crisis 
(statistically associated to Osserman stage), we built a 
scoring system according to the odds ratio of Osserman 
stage (1-2A, 2B, 3-4), BMI (<28, 28), duration of symptoms 
(<1 year, 1-2 years, >2 years) and association with a 
pulmonary resection (fig. 1). This model helped in creating 
four classes (fig. 2) with increasing risk of respiratory failure 
(Group 1: 6%; Group 2: 10%; Group 3: 25%; Group 4: 50%; 
accuracy=85,5%; specificity=93,75%; sensibility=36,84 %). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion: Our model allowed in stratifying patients’ risk 
and in predicting the occurrence of postoperative myasthenic 
crisis. Moreover, it could help anesthesiologist's decision on 
the duration of intubation. Further studies based on larger 
series are needed to confirm these preliminary data. 
 
Keywords: myasthenia gravis, Thymectomy, myasthenic 
crisis 
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Thoracic Surgery, Tor Vergata University, Rome/ITALY 
 
Background: Thymomatous myasthenia gravis represents a 
peculiar and severe disease. This study is aimed at 
evaluating if features specifically related to the neoplasm (i.e. 
stage, histology, biology) may be significant predictors of 
neurological outcome after thymomectomy and viceversa 
neurological variables can affect the neoplasm evolution in a 
precise clinical class (Class III according to the Myasthenia 
Gravis Foundation of America) of myasthenia gravis. 
 
Methods: We performed a retrospective analysis of 35 
patients (16 male, 19 female) with thymoma and class III 
myasthenia gravis undergoing extended transternal 
thymectomy plus thymomectomy between 1985 and 2005. 
Class III was identified as a moderate weakness 
predominantly affecting limb or axial muscles (type a) or 
oropharyngeal muscles (type b). Patients operated before 
2000 and therefore classified according to the Osserman’s 
classification were retrospectively re-classified. Oncological 
endpoints was disease-free survivals. Neurolgical outcome 
was complete stable remission. As oncological predictors of 
poor outcome were considered age (>55), sex (male), 
Masaoka stage (II-III), histology according World Health 
Organization (B2-B3), incomplete resection and cell-cycle 
protein (p53 high-, p21 low-, p27 low) and glucose 
transporter-1 and vascular endothelial growth factor 
expressions. Neurological poor predictors were sex (male), 
symptom-duration (<12 months), quality of life levels 
(physical and mental component summaries SF-36 below 
median value), Myasthenia gravis score, steroid-use, oro-
pharyngeal involvement, histology (B2-B3), hyperplastic 
residual thymus and evidence of ectopic thymic tissue.  
 
Results: There was no perioperative mortality. Disease-free 
survival rate were 67% at 5 and 56% at 10 years, 
respectively. At univariate analysis significant negative 
predictors were stage II-III (p=0.041), incomplete resection 
(p=0.019), B2-B3 histology (p=0.007) and cell-cycle protein 
expression (p=0.001), the latter resulting as the sole 
predictor at multivariate (p=0.003). Complete stable 
remission rate was 52% at 10 and 66% at 15 years, 
respectively. At univariate analysis significant negative 
predictors of complete stable remission were those related to 
the tumor and namely B2-B3 histology (p=0.021), incomplete 
resection (p=0.007) and cell-cycle protein expression 
(p=0.032). Traditional factors resulted marginal significant or 
non significant. No factor prevailed at multivariate analysis. 
 
Conclusion: Incomplete resection of thymoma, B2-B3 
histology and cell-cycle protein expression resulted the most 
significant predictors for both oncological and neurological 
poor outcome. Whereas traditional neurological factors 
resulted marginally or non significantly affecting the 
neurological outcome.These findings entails that 
thymomatous myasthenia should be considered a different 
neurological entity from the nonthymomatous one.  
 
Keywords: myasthenia gravis, Thymomas, Thymectomy, 
Complete remission 
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Background: Although the molecular genetics possibly 
underlying thymoma pathogenesis have been extensively 
studied the etiology of human thymoma remains poorly 
understood. Based on its association with the autoimmune 
disease myasthenia gravis (MG) and the consistent finding 
that murine polyomavirus induces thymomas in mice we 
tested the presence of Human Polyomavirus 7 (HPyV7) in 
human thymic epithelial tumors. 
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Methods: We applied HPyV7 DNA Fluorescence in situ 
hybridization (FISH), DNA PCR and immunohistochemistry 
(IHC) in 37 thymomas (19 female, 18 male; mean age 58.3 
years; range 34 – 82 years). Of these, 26 were previously 
diagnosed with MG. In addition, 2 thymic carcinomas and 20 
fetal thymus tissues were tested for HPyV7. 
 
Results: HPyV7 FISH revealed specific nuclear hybridization 
signals within the thymoma cells of 23 thymomas (62.2%). 
Fifteen thymomas revealed strong to very strong 
hybridization signals, whereas 8 revealed only weak 
positivity. With one exception the HPyV7 FISH data highly 
correlated with the HPyV7 DNA-PCR data. IHC showed the 
presence of HPyV7 on the translational level and 
immunohistochemical double stainings confirmed the 
presence of HPyV7 in the epithelial thymoma cellular 
compartment. One thymus carcinoma was HPyV7 positive 
the other negative. All fetal thymus tissues were tested 
HPyV7 negative. 
 
Conclusion: We conclude that HPyV7 is frequently present 
in human thymic epithelial tumors and absent in fetal thymic 
tissues. No convincing association on HPyV7 and MG could 
be found. In as much HPyV7 is of relevance to human 
thymomagenesis remains to be established.  
 
Keywords: thymoma, Human Polyomavirus 7 
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O2.1: TARGETED CANCER GENOME SEQUENCING IN 
THYMIC EPITHELIAL TUMORS 
 
Andre Moreira1, Robert Mcmillan2, Helen Won1, James 
Huang2, Gregory Riely3, Marc Ladanyi1, Michael Berger1  
1Pathology, Memorial Sloan Kettering Cancer Center, New 
York/UNITED STATES OF AMERICA, 2Surgery, Memorial 
Sloan Kettering Cancer Center, New York/UNITED STATES 
OF AMERICA, 3Medicine, Memorial Sloan Kettering Cancer 
Center, New York/UNITED STATES OF AMERICA 
 
Background: Thymomas and thymic carcinomas (TCA) are 
rare tumors. There have been very few studies dedicated to 
the understanding of the biology of these tumors. An 
improved understanding of the molecular characteristics of 
thymoma and TCA may lead to a better comprehension of 
tumorigenesis, and more importantly lead to new therapeutic 
targets, thus opening new treatment options for these 
patients.  
 
Methods: 13 pairs (tumor and normal tissue) of paraffin-
embedded tissue from thymic carcinoma and 6 pairs of 
thymoma WHO type B3 were evaluated by exon capture of 
275 cancer related genes (Agilent SureSelect Target 
Enrichment system), followed by next-generation sequencing 
(Illumina HiSeq). This approach identifies all sequence 
variants, small insertions and deletions, and copy number 
alterations involving the target genes. 
 
Results: Mutations were identified in 11 of 13 (85%) TCA 
with median of 1 mutation per tumor (range 0-26).all TCA 
were classified as squamous cell carcinoma, one with 26 
mutations was a CD5 positive poorly-differentiated 
carcinoma. The most mutated genes were TP53 (n=3), 
SMAD4 (n=2) and CYLD (n=2); and chromatin remodeling 
genes KDM6A (n=3), SETD (n=2), MLL3 (N=2), MLL2 (n=2). 
TP53 and KDMA6 were seen as a single mutation in one 
tumor each.. In this small sample, tumor with TP53 appear to 
have a more aggressive behavior. All 3 patients presented 
as Masaoka stage 4, received neoadjuvant therapy. 2 
patients died of disease (mean survival 2.2years). In contrast 
2 patients with stage 4 without TP53 mutations are alive with 
disease and 2 other died of unrelated cause. In contrast, in 
Thymoma B3, mutations were identified in 4 out of 6 tumors 
evaluated. 1 mutation was identified per tumor. Mutations in 
BCOR (BCL6 co-repressor) were seen in 3 thymomas and 
MLL3 (involved in histone methylation) in one tumor. 
 
Conclusion: Genomic Exon sequencing of cancer target 
genes in thymic epithelial tumors shows a low frequency of 
mutation. However, there is a different pattern of molecular 
alterations between thymic carcinoma and B3 thymomas. 
Thymic carcinomas have more mutations in TP53 gene 
whereas B3 thymomas have a higher frequency of mutations 
in BCOR gene. 
 
Keywords: genomic, thymoma, thymic carcinoma 
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Mirella Marino1, Federica Ganci2, Carmen Vico3, Andrea 
Sacconi2, Etleva Korita2, Enzo Gallo1, Domenico Vitolo4, 
Federico Venuta5, Francesco Facciolo6, Edoardo 
Pescarmona1, Giovanni Blandino2, Francesco Fazi3  
1Pathology, Regina Elena National Cancer Institute, 
Rome/ITALY, 2Translational Oncogenomics, Regina Elena 
National Cancer Institute, Rome/ITALY, 3Medico-Surgical 
Sciences And Biotechnologies, University La Sapienza, 
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Pathology, University La Sapienza, Rome/ITALY, 5Thoracic 
Surgery, University La Sapienza, Rome/ITALY, 6Thoracic 
Surgery, Regina Elena National Cancer Institute, 
Rome/ITALY 
 
Background: Mature microRNAs (miRNAs), as new class of 
modulators, control gene expression and have been recently 
subjected to extensive characterization in several normal and 
tumor systems. These small single-stranded RNA molecules 
showed both diagnostic and prognostic values. Whereas 
mRNA transcript profiling is technically challenging, requiring 
snap-frozen fresh material, miRNAs, due to their small size 
and stability, can be studied in formalin-fixed paraffin 
embedded (FFPE) tissue. Since miRNAs frequently target 
hundreds of mRNAs, miRNA regulatory pathways and their 
deregulation are complex. Growing evidence indicates that 
targeting microRNAs biogenesis and pathways could allow 
the development of novel RNA-based drugs with anticancer 
activity. 
 
Methods: FFPE tumor and normal tissues from the Regina 
Elena Cancer Institute and Policlinico Umberto I, Sapienza 
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University of Rome, were included in the study. Epithelial 
cell-rich areas from representative FFPE Thymic Epithelial 
Tumor samples belonging to different histological subtypes 
and matched normal peritumoral thymic tissues were 
considered. Patients who underwent any previous 
radiotherapy or chemotherapy treatment or with history of 
any other anticancer therapy were excluded. RNA from 54 
tumor and 12 normal samples was extracted by miRneasy 
FFPE kit (Qiagen) and hybridized by the use of the Agilent 
Platform. The Human miRNA Microarray from Agilent 
contains probes for 906 human microRNAs from Sanger 
database Rel.16. After the statistic and bioinformatic 
analyses, signal processing and quality control, the different 
expression of the identified miRNAs was validated by 
quantitative RT-PCR (RT-qPCR) in additional tumor 
samples. The analysis included unsupervised and 
supervised methods. 
 
Results: We found 9 upregulated and 5 downregulated 
miRNAs in TET vs normal thymic tissue. Data about the 
deregulation of miRs by RT-qPCR using a representative 
subgroup of samples are in agreement with results obtained 
from the array. In addition, preliminary results show the 
presence a group of miRNAs differentially expressed among 
TET subtypes (A, AB, B1 vs B2, B3 vs Carcinoma, 
according to the 2004 World Health Organization 
classification). Finally, by in silico analysis we identified 
putative target genes of the 14 deregulated miRs, some of 
them being important genes involved in cell proliferation and 
prognosis in different tumor systems. 
 
Conclusion: In a well-characterized retrospective tumor 
series, we identified miRNAs able to differentiate TET vs 
normal thymic tissue and among prognostically-grouped TET 
histotypes that may be useful in the management of this 
disease. Moreover, we identified several putative target 
genes known to be involved in thymic carcinogenesis and in 
the maintenance and spreading of this tumor. 
 
Keywords: bioinformatics, microRNA, Thymic Epithelial 
Tumors, miRNA Microarray 
 
 
ORAL ABSTRACT SESSION II 
Saturday, September 7, 2013 – 10:00 – 11:00 
O2.3: IS SACRIFYING PHRENIC NERVE DURING 
THYMOMA RESECTION WORTHWHILE? 
 
Olaf Mercier1, Sarah Hamdi1, Elie Fadel1, Sacha Mussot1, 
Dominique Fabre1, Benjamin Besse2, Thierry Le 
Chevalier1, Philippe Dartevelle1  
1Centre Chirurgical Marie Lannelongue, Le Plessis 
Robinson/FRANCE, 2Department Of Cancer Medicine, 
Institut Gustave Roussy, Villejuif/FRANCE 
 
Background: To determine whether involved phrenic nerve 
(PN) could be spared during thymoma resection.To 
determine whether involved phrenic nerve (PN) could be 
spared during thymoma resection. 
 
Methods: A retrospective study was conducted on patients 
who underwent resection of thymoma adherent, on digital 
palpation, to at least one PN in our institution between 1998 - 
2012. An en-bloc resection of the tumor and the invaded PN 
was performed unless both PN involved or compromised 
lung function leading to PN-sparing tumor removal, when 
feasible (PN adherent to the edge of the tumor without 
preoperative palsy). Postoperative radiation therapy was 
given to patients with spared PN or in Masaoka stage 3 and 
4. 
 
Results: There were 117 patients with a mean age of 57 
years [range, 28-84]. PN was spared in 76 patients (65%) 
and removed in 41 (35%). Masaoka classification showed 68 
stage-3 (58%) and 49 stage-4 (42%) and was similar 
between both groups. On permanent histology, 6 (14%) of 
the resected PN were not involved whereas a postoperative 
PN permanent palsy was found in 8 (11%) patients where 
the PN was spared. Postoperative mortality and morbidity 
were 0% and 6.6% in spared group and 2.4% and 4.9% in 
resected group, respectively without significant difference. 
Recurrence rate was significantly higher in spared group 
(39.5% vs 19.5%; p=0.02) but the 5-year disease-free 
survival rates (57% vs. 70%, p=0.08) and overall 5-year 
survival (74% vs. 88%, p=0.6) were not significantly different 
between spared and resected PN, respectively. 
 
Conclusion: Sparing PN during thymoma resection 
achieved good long term and disease-free survivals in high-
risk patients comparable to en-bloc PN resection. However, it 
carried a risk of higher risk of recurrence despite adjuvant 
radiation therapy. It should be reserved to patients with both 
PN involved or compromised lung function contraindicating 
any PN resection. 
 
Keywords: Thymoma surgery, Phrenic nerve 
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Background: Thymic epithelial neoplasms (TENs) represent 
a rare entity with poor prognosis and limited systemic 
treatment options, particularly in advanced stages and/or in 
thymic carcinomas (TC). The aim of this study was to assess 
the clinical benefit, the efficacy and toxicities of agents for 
patients (pts) with a refractory TEN enrolled in Phase I trials. 
 
Methods: We reviewed retrospectively pts with advanced 
pretreated TEN enrolled in Phase I trials at the Institut 
Gustave Roussy (SITEP) between 1994 and 2012. Toxicities 
were reported and scored according to NCI CTCAE version 
3.0. Efficacy was assessed using RECIST version 1.0. 
 
Results: Twenty-two treated pts were enrolled (15 with TC, 
7 with thymomas). The median number of prior systemic 
therapies was 2 (1-8). The median age was 50 years (range 
23-72), and 4 females were treated. Treatment received 
were mTOR inhibitor (mTORi) in 4 of pts, antiangiogenic 
agents (AA) in 7 pts, and other targeted therapies in 8 pts. 
The median follow-up time was 22.1 months (range, 1.25-
77.79 months). Autoimmune associated disease (AID) was 
reported in 6 pts. 36% had grade III/IV toxicity, 77% grade I/II 
toxicity and no toxic death was reported. AID exacerbated in 
one patient. One patient experienced a complete response 
(CR) and 3 a partial response (PR); 16 pts had stable 
disease (median 6.6 months) and 2 had a progressive 
disease. Objective response rate (ORR) was 18%, 29% for 
thymoma and 13% for TC. The median overall survival was 
54.5 months (95% CI 25-75.50 months), 78 for thymoma and 
46 for TC. The median progression free survival (PFS) was 
6.6 months (95% CI 1.35-11.59 months), 6.3 for thymoma 
and 6.8 for TC. Median PFS was 11.6 months for mTORi, 
6.9 for AA, and 6.6 for other targeted therapies. 
 
Conclusion: Phase I trials appear as a sound therapeutic 
option in TENs pts progressing after standard treatments. 
Use of AA and mTORi seem to yield a good clinical 
response. Novel targeted therapies might be tested in Phase 
I trial setting in a biology-oriented approach rather than a 
stochastical one. We are currently offering a molecular 
profiling in our patients (MOSCATO trial) for a better 
selection of appropriate Phase I trial. 
 
Keywords: mTOR inhibitors, phase I trials, thymic 
malignancies, antiangiogenic agents 
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O3.1: A MULTICENTER PROSPECTIVE STUDY OF 
CARBOPLATIN AND PACLITAXEL FOR ADVANCED 
THYMIC CARCINOMA : WEST JAPAN ONCOLOGY 
GROUP 4207L 
 
Yoshihito Kogure1, Fumihiko Hirai2, Takeharu 
Yamanaka3, Kenichi Taguchi2, Koji Takeda4, Haruko 
Daga4, Tatsuo Kimura5, Junichi Shimizu6, Kaoru Tanaka7, 
Yasuo Iwamoto8, Akira Ono9, Hidefumi Sasaki10, Junya 
Fukuoka11, Kenichi Nishiyama12, Takashi Seto2, Yukito 
Ichinose2, Kazuhiko Nakagawa7, Yoichi Nakanishi12  
1Respiratory Medicine, Nagoya Medical Center, 
Nagoya/JAPAN, 2National Kyushu Cancer Center, 
Fukuoka/JAPAN, 3National Cancer Center Hospital East, 
Kashiwa/JAPAN, 4Osaka City General Hospital, 
Osaka/JAPAN, 5Osaka City University, Osaka/JAPAN, 6Aichi 
Cancer Center Hospital, Nagoya/JAPAN, 7Kinki University 
School of Medicine, Osaka/JAPAN, 8Hiroshima City Hospital, 
Hiroshima/JAPAN, 9Shizuoka Cancer Center, 
Nagaizumicho/JAPAN, 10Nagoya City University Graduate 
School of Medicine, Nagoya/JAPAN, 11Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki/JAPAN, 
12Kyushu University Hospital, Fukuoka/JAPAN 
 
Background: Thymic carcinoma (TC) is a rare malignant 
tumor originated within the thymus gland and is associated 
with a poor prognosis, differing from thymoma which is the 
most common type of thymic malignant neoplasm. No results 
of clinical trials focusing on TC have been reported. This 
single-arm study evaluated carboplatin and paclitaxel (CbP) 
in previously untreated patients (pts) with advanced TC. 
 
Methods: Chemotherapy-naïve pts with Masaoka’s stage III 
to IVb, ECOG PS 0 to 1, and more than 20 years old were 
eligible. The study treatment consisted of carboplatin (area 
under the curve 6) and paclitaxel (200 mg/m2) every 3 weeks 
for a maximum of 6 cycles. The primary endpoint was 
objective response rate (ORR) by extramural assessment. 
Secondary endpoints included overall survival (OS), 
progression-free survival (PFS), and safety. All pts were 
followed-up until 24 months (mo) after last enrollment. Based 
on the SWOG 2-stage design, the planned sample size of 40 
pts was determined to  
reject the ORR of 20% under the expectation of 40% with a 
power of 0.85 and a type I error of 0.05. 
Results: From May 2008 to November 2010, 40 pts were 
enrolled from 21 centers. Of 39 evaluable for analysis, the 
median age was 62 years (range, 36–84); 23/16 
males/females; 3/10/26 with Masaoka’s stage III/IVa/IVb; 
9/11/19 with squamous cell carcinoma/poorly differentiated 
neuroendocrine carcinoma/other types. The median number 
of cycles was 6. There was 1/13 complete/partial responses 
with an ORR of 36% (95% CI, 21–53%; P = 0.031). The 
median PFS was 8.1 mo (5.4-13.1 mo) while OS did not 
reach the median value. The 1-year and 2-year survival rates 
were 85% (69–93%) and 71% (54–83%), respectively. Major 
adverse event was grade 3–4 neutropenia in 34 pts (87%). 
Two cases (5%) of grade 3 febrile neutropenia, neuropathy, 
and arthralgia were observed, respectively. There was no 
treatment-related death. 
 
Conclusion: CbP showed higher efficacy in advanced TC as 
compared with anthracycline-based chemotherapy which is 
the current standard for the treatment of thymoma. Our 
results established that CbP, one of the standard treatments 
for non-small cell lung cancer, also serves as a key 
chemotherapy regimen for TC. 
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Background: There are few treatment options for patient 
with advanced thymic malignancies and utility of many of the 
available chemotherapies are limited by cumulative toxicity 
such as neuropathy (taxanes) and cardiomyopathy 
(anthracyclines). We designed this study to look at single 
agent amrubicin, a third generation anthracycline and 
topoisomerase II inhibitor with limited cardiac toxicity, in 
patients with advanced thymic malignancies.  
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Methods: Eligible patients have confirmed thymic 
malignancy (thymoma (T) or thymic carcinoma (TC)) with 
progression or relapse after at least 1 prior chemotherapeutic 
regimen, and adequate organ function including left 
ventricular ejection fraction (LVEF) of >50%. The initial 
treatment plan consisted of amrubicin at 40 mg/m2 IV days 1-
3 repeated in 3-week cycles. The study is a Simon 2-stage 
design based on a null hypothesis of a true response rate 
<5%, with 90% power to detect a 20% true response rate 
and a plan to accrue 12 evaluable patients in stage 1, then if 
at least 1 response is seen, to add 25 additional evaluable 
patients in stage 2 for a total of 39 patients. 
 
Results: Enrollment was initiated in July 2011. Here, we 
report on the first 12 patients, all enrolled at Stanford 
University over a 19-month period. Of the first 12 patients 
enrolled, 11 were dosed. All were pre-treated (5 with prior 
anthracycline). There were 5 women and 7 men; age range 
of 30-67 years old; 6 were of Asian ethnicity, 5 were non-
Hispanic White and 1 was Hispanic. After enrollment of the 
first 8 patients, of whom 3 were hospitalized with febrile 
neutropenia (FN) (38%), the study was amended to a 
starting dose of 35 mg/m2 days 1-3 repeated in 3-week 
cycles. Other than FN in those 3 patients, G4 
thrombocytopenia in 1 patient, and treatment-related G3 
fatigue in 2 patients, other toxicities were generally mild and 
well tolerated. No significant changes in LVEF have been 
noted on serial echocardiograms. Of the 11 treated patients, 
there were 3 partial responses (2 T and 1 TC), 7 with stable 
disease for at least 4 cycles, and 1 with progressive disease 
(PD) after 2 cycles (TC). Of the 11 treated patients, only 1 
patient, with PD after C2, has stopped before completing 6 
cycles, and 5 to date have tolerated >10 cycles (others are 
still on treatment and may reach that number), with 15 cycles 
as the highest number to date.  
 
Conclusion: Amrubicin, at 35 mg/m2 IV days 1-3 on a 3-
week cycle, shows promise as a single agent in pre-treated 
patients with thymoma and thymic carcinoma with a 27% RR 
in the first 11 treated patients. This exceeded the threshold 
for proceeding to step 2 and the study will now continue to a 
total of 39 patients and has expanded to other sites including 
Indiana University. 
 
Keywords: amrubicin, advanced thymic malignancy, 
chemotherapy 
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O3.3: INTENSITY MODULATED RADIOTHERAPY FOR 
THYMOMA WITH PLEURAL RELAPSE 
 
Changlu Wang1, Wentao Fang2, Lanting Gao1  
1Radiation Oncology, Shanghai Chest Hospital, 
Shanghai/CHINA, 2Department Of Thoracic Surgery, 
Shanghai Chest Hospital, Shanghai/CHINA 
 
Background: It is always challenging to deal with a primary 
stageΦa thymoma with pleural involvement or pleural 
recurrence after thymectomy. We tried IMRT for some 
patients after we found extended surgery is impossible for 
them and systemic chemotherapy resulted in failure. 
 
Methods: From Apr 2009 to Feb 2013, totally 27 patients 
have been irradiated in our department with IMRT, targeting 
at pleural implants. The gender ratio was 18:9(male vs 
female). There were 3 B1, 2 B2, 21 B3 and 1 carcinoid 
respectively, categorized by WHO classification. Two 
patients were primary stageΦa, while the other 25 were 
diagnosed as post operative recurrence. The median time of 
recurrence was 40 (6-96) months The GTV countering 
covered visible lesions and the smooth pleura among them, 
usually forming an arch-shaped field. Prophylactic dose was 
given below 30Gy, and boost dose to visible tumor was given 
below 50Gy. Once out-field recurrence occurred, a second or 
third course of IMRT would also be given. 
 
Results: Among all 27 patients, 25 (92.6%) showed a more 
than 50% tumor regression within 3 months after IMRT. One 
patient showed tumor progression after 18Gy radiation, 
because myasthenia gravis exacerbation prevented her from 
further radiotherapy. One carcinoid patient showed no 
response 4 months after a 40Gy IMRT. Five patients 
developed out-field recurrence and received a second 
course of IMRT. The median progression free survival time 
was 27 months (3-45). Four patients suffered from radiation 
induced peumonitis of 3 degree, and symptoms were well 
relieved after medical control. Three patients developed 
ipslateral thorax contracture about 3 years after radiotherapy. 
 
Conclusion: IMRT has excellent effect on local tumor 
control for thymoma with pleural relapse. Prophylactic dose 
is advised to be blow 30Gy for concern of dose hot-spot 
when part-field of the first IMRT overlaps that of the second 
IMRT. RT induced peumonitis is the main toxicity. 
 
Keywords: radiotherapy, thymoma, pleural dissemination 
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O3.4: DOES POST-OPERATIVE RADIATION IMPACT 
SURVIVAL AFTER COMPLETE SURGICAL RESECTION 
OF MASAOKA STAGE IIB THYMOMA? A POPULATION 
BASED ANALYSIS IN 228 PATIENTS 
 
Benny Weksler, Manisha Shende, Katie Nason, Arjun 
Pennathur  
Cardiothoracic Surgery, University of Pittsburgh Medical 
Center, Pittsburgh/PA/UNITED STATES OF AMERICA 
 
Background: While postoperative radiation is commonly 
advocated in patients with Masaoka Stage IIB thymoma, the 
benefit of adjuvant radiation is unclear in patients who have 
undergone a complete surgical resection. The rarity of the 
disease has prevented proper randomized controlled studies. 
The goal of this study was to determine the effect of adjuvant 
radiation therapy (RT) in overall and disease-specific survival 
in patients with Masaoka stage IIB thymoma, who have 
undergone a complete resection. 
 
Methods: The SEER (Surveillance, epidemiology and end 
result) database is a NCI sponsored registry that covers 28% 
of the U.S. population and captures 98% of all cancer cases 
within the surveyed areas. We queried SEER for all patients 
with stage IIB thymoma who underwent complete surgical 
resection and survived more than 30 days after diagnosis. 
Both overall survival and disease specific survival was 
determined using the Kaplan-Meier method and compared 
using the log-rank test. The hazard ratio for death, controlling 
for confounding variables, was determined using a Cox 
proportional hazard model. Significance was set as p<0.05. 
 
Results: We identified 228 patients with stage IIB thymoma 
who underwent complete resection. Adjuvant postoperative 
radiation therapy was given to 137 (60.1%). Groups were 
similar in age, sex, and tumor size, but there were more 
Caucasians in the RT group 48/101 (57.8%) vs 100/167 
(73.5%), p=0.018. Overall survival for patients receiving 
adjuvant RT was 169.7 months (95% CI, 150.0-189.5) 
versus 153.4 months (95% CI, 121.6-185.2) in patients not 
receiving RT (p=0.664). Thymoma specific survival was also 
not improved with adjuvant RT (p=0.521). Multivariate 
analysis did not show radiation therapy, sex, tumor size, and 
WHO histology to significantly affect overall survival. 
 
Conclusion: This large population based study shows that 
postoperative adjuvant radiation therapy does not appear to 
improve survival in completely resected patients with stage 
IIB thymoma. Further studies on the role of postoperative 
radiation therapy in stage IIB thymoma are needed. 
 
Keywords: radiation therapy, Stage IIB thymoma, Survival, 
Population based study 
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P1.01: GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY 
AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE 
(AQUA) IN A THYMIC MALIGNANCY TISSUE 
MICROARRAY (TMA) 
 
Jonathan Riess1, Robert West2, Sukhmani Padda1, 
Michelle Dean3, Alexander Klimowicz3, Chuong Huong4, 
Joel Neal1, Heather Wakelee1  
1Medicine, Division Of Oncology, Stanford University School 
of Medicine, Stanford/California/UNITED STATES OF 
AMERICA, 2Pathology, Stanford University School of 
Medicine, Stanford/California/UNITED STATES OF 
AMERICA, 3Functional Tissue Imaging Unit, Tom Baker 
Cancer Center, University of Alberta, Alberta/CANADA, 
4Cardiothoracic Surgery, Division Of Thoracic Surgery, 
Stanford University School of Medicine, 
Stanford/California/UNITED STATES OF AMERICA 
 
Background: Thymoma is a rare malignancy, with a paucity 
of data on its biology and on the role of targeted 
therapeutics. Wnt, notch and sonic hedgehog pathway 
interactions between thymocytes and thymic stroma are 
important to both thymus and T-cell development. 
AQUAnalysis® is a digital image analysis software that 
continuously measures multiplexed protein expression and 
has the potential to overcome limitations of small sample 
sizes and tissue heterogeneity in the tumor 
microenvironment. We analyzed a thymoma TMA for gli1, 
notch1 and CTNNB1 expression by AQUA® as surrogate 
markers of activity of the sonic hedgehog, notch and wnt 
pathways, respectively. We hypothesized this preclinical 
screen may provide rationale for attacking these pathways 
with targeted therapeutics in thymoma.  
 
Methods: A TMA was constructed from 68 patients with 
thymic malignancies and 8 benign thymic controls at 
Stanford University School of Medicine (Stanford, CA). Gli1, 
notch1 and beta-catenin expression were assayed using 
quantitative fluorescent immunohistochemistry at the Tom 
Baker Cancer Center (Alberta, Canada). The TMA was 
stained with anti-gli1 rabbit mAb (monoclonal antibody), 
clone EPR4523 (Epitomics, Burlingame, CA, USA); anti-
Notch1 rabbit mAb, clone EP1238Y (Epitomics, Burlingame, 
CA, USA); and anti-beta-catenin mouse mAb, clone ȕ-
Catenin-1 (Dako Mississauga, ON, Canada) using a Dako 
autostainer. To isolate expression of these stem-cell pathway 
proteins separately in the tumor and the lymphocytes, the 
TMA was also stained with anti-pan-cytokeratin guinea pig 
mAb (Acris, San Diego, CA, USA); anti-vimentin rat mAb, 
clone 280618 (R&D Systems, Minneapolis, MN, USA); and 
anti-CD45 rabbit mAb, clone EP322Y (Epitomics, 
Burlingame, CA, USA). Automated image acquisition was 
performed using an Aperio Scanscope FL (Aperio Inc., Vista, 
CA, USA). Images were then analyzed using the 
AQUAnalysis® program, version 2.3.4.1. A tumor-specific 
mask and a tumor cytoplasmic mask were generated to 
distinguish thymoma cells from surrounding stromal tissue by 
thresholding the pan-cytokeratin images to identify pan-
cytokeratin positive cells as tumor cells and define the tumor 
cytoplasm Statistical analysis was performed using SAS 
Enterprise Guide v5.0 (Cary, NC). Two-tailed t-tests were 
used to compare the differences between thymic tumor and 
benign control tissue. ANOVA and Dunnett’s t-test was used 
to compare differences in gli1, notch1, and CTNNB1 
expression by WHO histology. 
 
Results: Demographics for 68 patients: M:F (53%/47%), 
Mean age at diagnosis: 55 years, WHO Histology: A (10%), 
B (57%), AB (24%), C (4%), unclassified (4%), Pathologic 
Masaoka Stage: I (46%), IIa (18%), IIb (4%), III (18%), IVa 
(9%) IVb (6%). No difference in gli1 (mean 211 vs. 201, 
p=0.31), CTNNB1 (mean 396 vs. 418, p=0.66) or notch1 
expression (mean 317 vs. 325, p=0.82) was noted between 
thymic tumors and controls. In a subset analysis, we found 
no significant differences by WHO histology compared to 
controls. 
 
Conclusion: AQUA® was used to help overcome limitations 
of analyzing protein expression in histologically 
heterogeneous thymic tumors and small sample sizes. We 
found no clinically or statistically significant increased 
expression of gli1, notch1, and CTNNB1 in thymoma 
compared to benign thymic tissue. Thus, this study provides 
no evidence for upregulation of the sonic hedgehog, notch or 
beta-catenin pathways in thymic tumors. 
 
Keywords: stem cell, tissue microarray, thymoma 
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Jonathan Riess1, Peiwen Kuo2, Christina Kong3, Robert 
West3, Sukhmani Padda1, Heather Wakelee1, Quynh Le2  
1Medicine, Division Of Oncology, Stanford University School 
of Medicine, Stanford/California/UNITED STATES OF 
AMERICA, 2Radiation Oncology, Stanford University School 
of Medicine, Stanford/CA/UNITED STATES OF AMERICA, 
3Pathology, Stanford University School of Medicine, 
Stanford/CA/UNITED STATES OF AMERICA 
 
Background: Thymoma is a rare malignancy with a paucity 
of data on biology. Thymic epithelial tumors are often 
admixed with developing T-lymphocytes in the 
microenvironment. Galectin-1 (gal-1) is a beta-galactosidase 
binding protein involved in T-cell development via thymic 
stromal and thymocyte interaction as well as thymocyte 
development through negative selection. Gal-1 also induces 
apoptosis of effector T-lymphocytes, promotes angiogenesis, 
and is a poor prognostic indicator when overexpressed in 
several tumor types. To our knowledge expression of gal-1 
has not been examined in thymic epithelial tumors. 
 
Methods: A TMA was constructed from 68 patients with 
thymic malignancies and 8 benign thymic controls at 
Stanford University School of Medicine (Stanford, CA). 
Immunohistochemical stains for galectin-1 (1:200 dilution; 
citrate pre-treatment; mouse monoclonal; Novocastra) were 
performed on 4 μM-thick TMA sections. Galectin-1 
cytoplasmic staining of the epithelial cell component was 
scored as negative (0), focal positive (1+), or strong positive 
(2+) by a Stanford pathologist, who was blinded to the 
clinical data. Gal-1 expression (0, 1, 2) was averaged for 
each patient sample. Statistical analysis was performed 
using SAS Enterprise Guide v5.0 (Cary, NC). Non-
parametric statistical analyses were used to compare 
average patient gal-1 expression between thymic tumors and 
benign thymic controls. 
 
Results: Demographics for 68 patients: M:F (53%/47%), 
Mean age at diagnosis: 55 years, WHO Histology: A (10%), 
B (57%), AB (24%), C (4%), unclassified (4%), Pathologic 
Maseoka Stage: I (46%), IIa (18%), IIb (4%), III (18%), IVa 
(9%) IVb (6%). Gal-1 expression was increased among 
thymic tumor tissue compared to unpaired controls (mean 
avg gal-1 expression 1.5 vs. 0.125, p=0.0012, Kruskal-Wallis 
test). Logistic regression of tumor vs. control thymus by gal-1 
generated a C-statistic of 0.845. A significant increase in gal-
1 expression was noted across all WHO thymoma subtypes 
except thymic carcinoma (type C) (p < 0.05, non-parametric 
ANOVA with post-hoc ranked Dunnett’s t-test). Among 11 
thymic tumors analyzed with paired adjacent resected benign 
thymus tissue from the same patient, a significant increase 
was noted in gal-1 expression among tumor compared with 
adjacent resected benign thymus (mean avg gal-1 1.82 vs. 
0.35, p=0.004, sign-rank test). 
 
Conclusion: Gal1 expression was increased among 
thymoma compared with benign thymus controls and paired 
resected benign thymus tissue. A robust C-statistic of 0.845 
indicates that gal-1 expression may discriminate tumor from 
benign thymus. Increased gal-1 expression was conserved 
across WHO histologic subtype except for thymic 
carcinoma—whose analysis was limited due to small sample 
size. We are continuing to investigate the biologic and 
clinical significance of increased gal-1 expression in 
thymoma. 
 
Keywords: galectin-1, immune markers, thymoma, tissue 
microarray 
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IN THYMOMA 
 
Anja Roden1, Eunhee Yi1, Sarah Jenkins2, Kelly 
Edwards2, Stephen Cassivi3, Randolph Marks4, Yolanda 
Garces5, MarieChristine Aubry1  
1Laboratory Medicine And Pathology, Mayo Clinic Rochester, 
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Background: Modified Masaoka staging has been 
suggested as a prognostic parameter for thymoma, although 
Moran et al proposed a new staging system. The prognostic 
role of histopathologic classifications and clinical features are 
controversial. Moderate interobserver agreement in 
morphologic classification hampers studies. We studied 
clinicopathologic parameters of thymoma in which multiple 
pathologists agreed upon a morphologic diagnosis. 
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Methods: Three pathologists reviewed 412 thymoma (1942-
2008) and classified them according to WHO, proposed 
Suster & Moran (S&M) and Bernatz classifications. Cases in 
which all pathologists agreed were studied further. Outcomes 
were analyzed with Cox proportional hazards regression 
models. 
 
Results: Figure 1 presents numbers of reviewed thymomas, 
morphologic agreement, available follow up and statistically 
analyzed cases. Follow-up (median 7.5 years, range 0-44) 
was available for 121 women and 111 men; 33 had 
recurrence and/or metastasis (5-year estimate 9.2%). 121 
patients died (5-year estimate 23.9%), 11 of disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
 
Table 1 summarizes the univariate analysis for overall (OS) 
and recurrence free (RFS) survival. Year of treatment was 
not significant. Multivariate analysis adjusted for WHO, S&M 
or Bernatz showed age, thymoma size and Masaoka as 
independent predictors of OS; thymoma size and Masaoka 
independently predicted RFS. Weight loss and resection 
status were additional predictors of OS; weight loss was an 
additional predictor of RFS when adjusted for S&M. 
Resection status was also an independent predictor for OS 
when adjusted for Bernatz. 
 
If adjusting for WHO or S&M and Masaoka and resection 
status, only Masaoka remained an independent predictor of 
RFS and OS. If adjusted for Masaoka, age and thymoma 
size were independent prognostic predictors of OS. A strong 
correlation between Masaoka and proposed Moran staging 
(correlation coefficient, 0.95) suggested that proposed Moran 
staging has similar prognostic strength as Masaoka. Table 
Legend: aComplete resection in 92.1% cases. bMicronodular 
(3.0%) and metaplastic (0.4%) thymoma were also identified 
 
Conclusion: Modified Masaoka staging is the strongest 
predictor of OS and RFS of thymoma when compared to 
resection status and morphologic classifications. Thymoma 
size is a prognostic parameter independent of Masaoka and 
morphology and should be considered for any new staging 
system. 
 
Keywords: WHO classification of thymoma, Modified 
Masaoka Stage, Thymoma size, Prognostic Predictors of 
thymoma 
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Background: The objective of this study is to see how the 
ITMIG recommendations changed the original Masaoka-
Koga’s classification of thymomas in our series. 
Methodes: Retrospective descriptive study of a series of 
patients who underwent resection of thymic tumors from 
June 1995 to May 2013. The original Masaoka-Koga’s 
classification was modified following the ITMIG 
recommendations (J Thorac Oncol. 2011;6 S1710-S1716). 
 
Results: During the study period 36 patients (19 women) 
were operated on Mean age of 55’3 years (range 29 to 75). 
The thymoma was the most common hystological type with 
31 (86%) patients from whom 8 (26%) presented with 
generalized myasthenia gravis (MG). As for the other 
patients, one had thymic hyperplasia and four had thymic 
carcinomas. Changes in tumour staging after applying the 
ITMIG recommendations are shown in the table. 
 
Resection approaches: 26 (72.2%) sternotomies, 5 (13.8%) 
posterolateral thoracotomies, 3 (8.3%) VATS (video-assisted 
thoracic surgery) resections, 1 (2.7%) anterolateral 
thoracotomy, 1 (2.7%) transcervical approach. In all cases 
but three complete resection was possible. Two patients 
(5.5%) presented with recurrence; one of them had a stage 
IVb thymoma. Both underwent a new resection. As for the 8 
patients with MG, 5 (62.5%) had a complete remission. One 
patient (2.7%) died in the postoperative period from sepsis 
by Staphylococcus aureus. After a mean follow-up of 88.3 
months (range from 1 to 193 months), 29 (80%) patients 
were alive. In the group of patients with thymoma, 5 died 
from non-related causes. From the 4 patients with thymic 
carcinoma, one is free from disease (after 5 months of 
follow-up), one patient was missing after 132 months of 
follow-up, one died from non-thymoma related and the other 
one died intraoperatively from rupture of the aortic arch. This 
last patient had been treated with induction chemo-
radiotherapy. 
 
Conclusion: The ITMIG recommendations modified the 
original Masaoka-Koga’s classification in more than a third of 
cases. We need larger series to see how this change in 
staging impacts survival. 
 
Keywords: Masaoka-Koga's classification, Thymic tumors, 
staging 
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P1.05: PLEURAL METASTASES OF THYMOMA IN 
PLEURODESED HEMITHORAX - DO WE NEED TO 
RETHINK THE TRANSCOELOMIC MECHANISM OF 
METASTATIC SPREAD? 
 
Sarah Hunt, Alan Kirk, Khalid Amer  
Thoracic Surgery, Golden Jubilee National Hospital, 
Glasgow/UNITED KINGDOM 
 
Background: Disseminated disease in thymic malignancy is 
typically confined to the thorax. The route of metastatic 
spread has been attributed to multiple mechanisms 
including; transplantation, implantation, lymphatic, 
haematogenous and most commonly transcoelomic – 
particularly where pleura is involved. This case report and 
literature review explores the nature of metastatic spread to 
the pleura in a patient who had undergone previous talc 
pleurodesis, and considers whether established mechanisms 
need to be reconsidered. 
 
Methods: Review of established literature on disseminated 
thymoma did not reveal a comparable case report. We 
searched literature databases PubMed and Cochrane, using 
search entries including; thymoma, dissemination, 
transcoelomic metastasis. We felt that this case report 
challenged the most current explantation of metatastic 
spread. A 53 year-old gentleman presented with pleuritic 
chest pain. His CTPA was negative. However the CT 
identified a large anterior mediastinal lobulated mass, 
extending into anterior pericardium. The mediastinum 
appeared to have associated pericardial thickening, with 
several pleural masses at the left hemithorax base. Biopsies 
identified thymoma tissue, stage B1. In 1998 and 2000 he 
was admitted to hospital with left-sided spontaneous 
pneumothoraces, and underwent a successful talc 
pleurodesis(2000) which obliterated the left pleural cavity 
and prevented any reoccurrence. In 2008 the gentleman 
underwent a routine chest x-ray for shortness of breath, this 
identified; abnormalities distorting the cardiac contours, 
thought not to be suspicious at this time, and otherwise 
normal. The man commenced neo-adjuvant chemotherapy 
which had limited effects on the size of the tumour. A radical 
thymectomy was performed on the 23/8/12. The mass was 
removed in two pieces plus three pleural lesions. Pleural 
options were limited due to pleurodesis. The histology 
identified a high grade B2 thymic tumour, with foci of 
squamous cell carcinoma(which were extensively present at 
the margins). No macroscopic disease was left in the 
 29 Journal of Thoracic Oncology • Volume 8, Supplement 1, September 2013                                  

mediastinum. Due to the relative chemo insensitivity, further 
management included mediastinal radiotherapy and interval 
scans. The pleural lesions awaited a further surgical decision 
as to whether it would be possible to resect the tissue via 
thoracotomy. 
 
Results: The regionalised nature of pleural involvement in 
this patient, in the context of an obliterated pleural space, 
suggested that transcoelomic mechanisms of metastatic 
spread was less likely. Literature has suggested that 
lymphogenous and haematogenous dissemination are less 
common in thymic malignancies, however this case may 
suggest that other methods of dissemination may be more 
significant than previously thought. 
 
Conclusion: This case prompts reconsideration of the 
predominant route of metastatic spread in thymic 
malignancy. Invasion and transcoelomic spread are reported 
frequently however it has been rarely seen to disseminate 
via the blood and lymph systems. Pleural dissemination is 
seen most frequently in thymic malignancy(in some series up 
to 25%). This case questions the route of dissemination via 
the transcoelomic route in an obliterated pleural space. 
Pathological studies of breast cancer spreading to pleura 
found them to be mostly lymphatic. With this in mind and the 
case discussed, some interesting questions are raised into 
the metastatic spread of thymic malignancies. 
 
Keyword: Thymoma, transcoelomic metastases, pleurodesis 
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PATIENTS UNDERGOING THYMECTOMY: A STUDY 
FROM UNITED KINGDOM. 
 
Luke Kelly, Felice Granato, Stephan Dreyer, Matthew 
Wickham, Alan Kirk  
Thoracic Surgery, Golden Jubilee National Hospital, 
DY/UNITED KINGDOM 
 
Background: Thymomas and thymic carcinomas are 
epithelial tumours arising from the thymic gland (TETs). The 
incidence in the United States is 0.15 per, 100,000 person 
years. In 10-15% of cases, TETs are associated with 
Myasthenia Gravis (MG). 
 
The role of haematological markers, such as acute phase 
proteins (APP), neutrophil to lymphocyte ratio (NLR) and 
platelet to lymphocyte ratio (PLR) is still uncertain. The aim 
of this retrospective study is to evaluate the pre-operative 
significance of APP, haemoglobin, NLR and PLR in patients 
with TETs undergoing thymectomy and to assess their 
impact on the clinical outcome of MG. 
 
Methods: Sixty consecutive patients undergoing thymic 
resection at a single institution from November 2008 to May 
2013 were retrospectively analysed. Age, gender, pre-
operative CRP, NLR, PLR, haemoglobin, albumin, 
myasthenia status and post-operative medical treatment 
were evaluated. Two patients with diagnosis of malignancy 
other than TETs were excluded from our study. Two groups 
were identified; Group A (patients with ETTs), Group B 
(patients with benign thymic disease or normal pathology). A 
subgroup of patients with myasthenia gravis and their 
medical management following thymectomy was also 
assessed. 
 
Results: There was no statistical significant difference in the 
preoperative mean values of haemoglobin, albumin, CRP, 
PLR and NLR between Group A and B (p>0.05). In patients 
with a diagnosis of myasthenia gravis, patients with no 
reduction in post-operative medical treatment following 
thymectomy were shown to have higher mean values of CRP 
and lower PLR values but these differences did not reach 
statistical significance (p>0.05) whereas mean NLR was 
approaching statistical significance (p=0.06). 
 
Conclusion: In this study, the pre-operative haematological 
markers evaluated did not show a significant elevation in 
patients with TETs when compared to those with benign 
thymic pathologies. Preliminary evidence suggests there 
may be a neutrophil mediated response in MG and this could 
influence the clinical improvement of these patients after 
thymectomy. Further studies are warranted in order to make 
definitive conclusions. 
 
Keyword: Thymic malignancy myasthenia markers 
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Background: Lymph node metastasis is not uncommon and 
important prognostic factor in thymic epithelial tumors. 
However, lymphatic metastasis pattern is still unknown. We 
investigated lymph node metastasis pattern of thymic 
epithelial tumors. 
 
Methods: Total of 223 patients underwent thymectomy for 
malignant thymic epithelial tumors were retrospectively 
reviewed. Stations of lymph node metastasis in patients who 
underwent lymph node dissection and station of lymph node 
recurrence in patients without initial lymph node metastasis 
were investigated. Lymph node station was divided into 
anterior mediastinal lymph nodes (perithymic lymph nodes), 
intrathoracic lymph nodes (any intathoracic lymph nodes 
except anterior mediastinal lymph nodes) and extrathoracic 
lymph nodes. Nomenclature of each station of intrathorcic 
lymph nodes follows that of generally used lung cancer 
lymph node station. 
 
Results: Lymph node metastasis was confirmed in 12 
patients. Eleven patients had metastasis in dissected lymph 
node during total thymectomy and one patient had 
recurrence at lymph node during follow-up. Lymph node 
metastasis rate according to the WHO type were 71% (3/42) 
in B2, 9.1% (3/33) in B3 and 16.2% (6/37) in C. There was 
no lymph node metastasis in 101 type A, AB and B1. 
Metastasis rate according to the Masaoka-Koga stages 
excluding lymph node factor were 28.1% (9/32) in III, 10.5% 
(2/19) in IVa and 33.3% (1/3) in IVb. There was no lymph 
node metastasis in 169 patients with stage I or II tumors. 
Mean tumor size was 8.9cm (4 -14). Lymph node 
metastases were confirmed at anterior mediastinal lymph 
nodes in 6 patients and at intrathoracic lymph nodes in 7 
patients. One patient had metastasis at both areas. Five 
patients (71.4%) with intrathoracic lymph node metastasis 
had metastasis at right paratracheal area. One patient with 
B2 thymoma invading chest wall had metastasis at right 
internal mammary lymph node and right hilar lymph node. 
One patient with right paratracheal lymph node metastasis 
also had metastasis at subcarinal lymph node. One patient 
with completely resected stage IIb type B3 thymoma had 
recurrences at subcarinal node and right middle lobe. Two 
patients with right paratracheal lymph node metastasis had 
recurrences at cervical lymph nodes. 
 
Conclusion: Anterior mediastinal and intrathoracic lymph 
node metastasis is not uncommon in malignant thymic 
epithelial tumors. Right paratracheal lymph nodes group is 
crucial station of lymphatic metastasis pathway in malignant 
thymic epithelial tumors. Right paratracheal lymph node 
should be dissected in locally advanced malignant thymic 
epithelial tumors. 
 
Keywords: right paratracheal node, lymph node metastasis, 
thymoma 
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P1.08: PET-CT EVALUATION OF METABOLIC TUMOR 
VOLUME IN EARLY AND INVASIVE THYMOMAS  
 
Marcelo Benveniste1, Cesar Moran2, Osama Mawlawi3, 
Stephen Swisher4, Patricia Fox5, Reginald Munden1, 
Edith Marom1  
1Diagnostic Imaging, MDAnderson Cancer Center, 
Houston/TX/UNITED STATES OF AMERICA, 2Pathology, 
MDAnderson Cancer Center, Houston/UNITED STATES OF 
AMERICA, 3Physics, MDAnderson Cancer Center, 
Houston/UNITED STATES OF AMERICA, 4Surgery, 
MDAnderson Cancer Center, Houston/UNITED STATES OF 
AMERICA, 5Statistics, MDAnderson Cancer Center, 
Houston/UNITED STATES OF AMERICA 
 
Background: Metabolic tumor volume assessment using 
positron-emission tomography (PET)–CT has a role for 
monitoring response to therapy in oncologic patients. 
Assessment of tumor volume above a specific SUV threshold 
has a potential promise to distinguish between early (Stage I 
and II) and advanced thymoma (stage III and IV) as well as 
high risk thymoma (Type B3) from low risk according to 
WHO Classification. It is important to differentiate these 
neoplasms before surgery, as patients with a worst 
histological type or locally advanced tumors require 
neoadjuvant chemotherapy that enables effective resection. 
Thus, tumor volumetric assessment could be used to direct 
those patients. This study assessed whether the volumetric 
standardized uptake value (SUV) measurements can predict 
advanced thymoma and whether it can separate type B3 
thymoma from low risk thymoma. 
 
Methods: We retrospectively reviewed FDG positron 
emission tomography (PET)-CT scans of 51 consecutive 
newly diagnosed patients with thymic epithelial malignancy. 
PET-CT findings documented were focal FDG activity: 
SUVbwmax, SUVbwmean, SUVbwpeak and total body 
volumetric standardized uptake value (SUV) measurements. 
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These were correlated with Masaoka-Koga staging and 
WHO classification. Wilcoxon rank-sum tests were used to 
assess association between SUV and pathological stage, 
cancer type, and classification. 
 
Results: Among the study patients, 37 had thymoma, 12 
thymic carcinoma, and 2 thymic carcinoid. Higher total tumor 
volume above SUV 3.5 was seen in patients with type B3 
thymoma than in those with type A, AB, B1, or B2 thymoma 
(p=0.0408). Total tumor volume above SUV 3.5 was higher 
in patients with advanced stage than in early stage disease 
(p=0.0008). Additionally, patients with thymic carcinoma or 
carcinoid demonstrated a higher total tumor volume above 
SUV 3.5 than in those with thymoma (p=0.0212). 
 
Conclusion: Metabolic tumor volume assessment is helpful 
in distinguishing early from advanced stage thymoma, low-
risk thymoma from more aggressive thymoma (type B3) and 
thymic carcinoma/carcinoid tumors from thymoma. 
 
Keywords: PET-CT, Metabolic Tumor Volume, thymoma 
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P1.09: 68GA-DOTA-CONJUGATE PEPTIDES AND 
[18F]FDG PET/CT IN THYMIC MALIGNANCIES 
 
Martina Sollini1, Armando Froio1, Antonio Chella2, Marco 
Lucchi3, Federico Rea4, Giulia Atti1, Roberto Boni5, 
Massimo Roncali1, Annibale Versari1, PaolaAnna Erba5  
1Nuclear Medicine, Arcispedale Santa Maria Nuova - IRCCS, 
Reggio Emilia, Reggio Emilia/ITALY, 2Pneumology, Azienda 
Ospedaliero-Universitaria Pisana, Pisa/ITALY, 3Thoracic 
Surgery, Azienda Ospedaliero-Universitaria Pisana, 
Pisa/ITALY, 4Thoracic Surgery, University of Padua, 
Padua/ITALY, 5Nuclear Medicine, University of Pisa, 
Pisa/ITALY 
 
Background: Thymic malignancies include different type of 
neoplasms characterized by different morphology of 
epithelial cells and degree of atypia. Variable different 
degree of somatostatin receptors (SSTR) expression may be 
present on cell surface and despite the in vitro demonstration 
of its inhibitory effect in thymic epithelial cells as well as on 
T-lymphocyte development through paracrine mechanisms, 
the use of octreotide alone or in combination with prednisone 
is still controverse even in presence of positive Octreoscan. 
Although Octreoscan shows high efficacy for whole body 
imaging (reported detection rate of 80-100%), there are 
some limitations. More recently, PET with 68Ga-DOTA-
conjugate peptides has brought about dramatic 
improvements in spatial resolution with promising results for 
the detection of SSTR expressing tumours, and provides 
prognostic information. The aim of this study is to investigate 
the pattern of 68Ga-DOTA-conjugate peptides and [18F]FDG 
uptake at PET/CT for thymic malignancies restaging and to 
compare their performances to CT findings as gold standard.  
 
Methods: We retrospectively evaluated 29 thymic 
malignancies patients (M/F=12/17; mean age 57 years; 
median age 60 years; range 35-78 years) affected by thymic 
neoplasms (type A n=2, AB n=2, B1 n=4, B2 n=4, B2/B3 
n=2, B3 n=7, C n=8). All patient after histological 
confirmation, performed both 68Ga-DOTA-conjugate peptides 
PET/CT and [18F]FDG PET/CT one month a part. Results of 
68Ga-DOTA-conjugate peptides and [18F]FDG PET/CT 
examinations were compared using CT findings as gold 
standard and correlate to histological type. The maximum 
standard uptake value (SUVmax) was calculated for both 
68Ga-DOTA-conjugate peptides and [18F]FDG PET/CT 
images.  
 
Results: 68Ga-DOTA-conjugate peptides PET/CT was able 
to correctly identify site of disease in 12(1/2 AB; 2/4 B1; 1/4 
B2; 4/7 B3; 4/8 C) cases and negative in 17 (2/2 A; 1/2 AB; 
2/4 B1; 3/4 B2; 2/2 B2/B3; 3/7 B3 and 4/8 C) while [18F]FDG 
PET/CT results negative in only 5 cases (1/2 AB;1/4 B2; 2/7 
B3; 1/8 C). Comparison between 68Ga-DOTA-conjugate 
peptides and [18F]FDG PET/CT are as follow: 14/29 68Ga-
DOTA-conjugate peptides-/[18F]FDG+; 2/29 68Ga-DOTA-
conjugate peptides+/[18F]FDG-; 10/29 both positive and 3/29 
both negative (Table 1).  
 
Table 1 
PET/CT FDG + FDG - Total 
68Ga-DOTA + 10 2 12 
68Ga-DOTA - 14 3 17 
Total 24 5 29 
 
SUVmax values not showed significant difference between 
68Ga-DOTA-conjugate peptides and [18F]FDG PET/CT (2.2-
9.1 and 2.1-9.8, respectively). In 5 patients all the CT 
detectable lesions presented 68Ga-DOTA-conjugate peptides 
uptake while for [18F]FDG this was observed in 14 cases. In 
the other cases we observed at least one measurable CT 
lesion without either 68Ga-DOTA-conjugate peptides and/or 
[18F]FDG uptake. Finally, in 5 cases 68Ga-DOTA-conjugate 
peptides and [18F]FDG PET/CT identify more lesions as 
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compared to CT, mainly localized at bone. No false positive 
findings were observed at 68Ga-DOTA-conjugate peptides 
PET/CT. 
 
Conclusion: In this series of thymic neoplasm at restaging a 
predominant [18F]FDG positivity was observed as compared 
to 68Ga-DOTA-conjugate peptides at PET/CT. 68Ga-DOTA-
conjugate peptides remains most frequently positive in AB, 
B1, B3 and C even. Concordant [18F]FDG-PET/CT and CT 
results were observed in 14/29 patients, detecting additional 
bone lesions in 5/29 cases. These findings may suggest a 
relative loss of SSTR expression during thymic malignancy 
progression and should be considered when planning SSTR-
analogues therapy.  
 
Keywords: [18F]FDG PET/CT, thymic malignancies, 68Ga-
DOTA-conjugate peptides PET/CT, somatostatin receptors 
expression 
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P1.10: ANALYSIS OF PROTEIN EXPRESSIONS AND 
GENETIC MUTATIONS OF THE C-KIT GENE IN 19 
PATIENTS WITH THYMIC CANCER - AN EXPERIENCE 
OF ONE C-KIT MUTATION POSITIVE PATIENTS 
TREATED WITH IMATINIB 
 
Takashi Seto1, Fumihiko Hirai1, Gouji Toyokawa1, Yoko 
Takeda1, Kenichi Taguchi2, Ryo Toyozawa1, Eiko 
Inamasu1, Tsukihisa Yoshida1, Yoshimasa Shiraishi1, 
Tomoyoshi Takenaka1, Masafumi Yamaguchi1, Mitsuhiro 
Takenoyama1, Yukito Ichinose2  
1Department Of Thoracic Oncology, National Kyushu Cancer 
Center, Fukuoka/JAPAN, 2Clinical Research Institute, 
National Kyushu Cancer Center, Fukuoka/JAPAN 
 
Background: Thymic cancer (TC) is a rare 
malignancyamong thymic tumors, and c-kit serves as one of 
the immunohistochemical (IHC) markers of TC. Although 
mutations of the c-kit gene are frequently observed in 
gastrointestinal stromal tumor (GIST), and the patients with 
c-kit positive GIST have been successfully treated with c-kit 
inhibitors such as imatinib, several reports recently identified 
mutations of the c-kitgene in patients with TC. Thus,we 
investigated mutations and protein expressions of the c-kit 
gene in patients with TC. 
 
Methods: IHC and genetic analyses (PCR and direct 
sequencing) were performed in nineteen patients with TC. 
 
Results: One of 19 (5%) patients with TC was identified to 
harbor the c-kit mutation, while c-kit protein expressionswere 
observed in 10 of 19(53%) TCs.Among the 10 c-kit positive 
TCsat protein levels,fourTCs were judged to be weaklyor 
focally stained. Case report: A 32-years-old female without 
any symptomswas diagnosed with TC (poorly differentiated 
squamous cell carcinoma) by thymicfine needle biopsy. 
Since the disease progressed even after treatments with 
carboplatin pluspaclitaxel and some investigational drugs, 
VATS lung biopsy was performed fora metastatic lung tumor, 
and revealed the tumor to be the same histology as that of 
the initial biopsy. The tumor showed immunoreactivity for 
CK903, P63, CD5, chromograninA, CD56, bcl-2 and c-kit, 
while no expressions of synaptophysin and hCG were 
observed. Furthermore, genetic analyses detected mutations 
of the c-kit gene in exon11 V559G (substitution-missense) 
and 1676 T> G (substitution). Based on this result, treatment 
with imatinib 400mg/day p.o. was administered from 
28/Mar/2013 and 20% of tumor regression was achieved 
approximately 3 month after the administration of the drug. 
 
Conclusion: The frequency of the c-kit sensitive 
mutationshas yet to be established; however, patients with 
TC harboring the c-kitmutations could benefit much from c-kit 
inhibitors. Since c-kit is one of the driver oncogenesin TCs, 
c-kit inhibitors such as imatinib could be one of the key-drugs 
for c-kit mutatedpatients with TC. A prospective global study 
is warranted to investigate the efficacy and safety of c-kit 
inhibitors for TCs harboring the c-kit mutations. 
 
Keywords: thymic cancer, c-kit, imatinib 
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P1.11: EXPRESSION OF EZRIN IN TUMOR CELLS 
CORRELATES WITH THE THYMOMA 
SUBCLASSIFICATION 
 
Qiangling Sun1, Wentao Fang2  
1Basic Research Laboratory, Shanghai Chest Hospital, 
Shanghai/CHINA, 2Department Of Thoracic Surgery, 
Shanghai Chest Hospital, Shanghai/CHINA 
 
Background: The histologic classification of thymoma has 
been attracting more controversy on account of 
morphological variation and tumor epithelial heterogenicity 
for the past several decades. Molecular profiling at gene or 
protein levels may elucidate the biological variance of tumors 
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and contribute to the pathological classification system that 
correlates better with biological, clinical and prognostic 
parameters. 
 
Methods: To investigate the roles of ezrin in thymic epithelial 
tumors, we examined the expression of ezrin in 39 type B 
tumors by tissue array and immunohistochemistry. The 
tumors consisted of 18 type B1, 11 type B2 and 10 type B3 
according to the World Health Organization histologic 
classification system and of 13 stageΣ, 13 stage Τ and 11 
stage Υ thymomas according to the Masaoka staging 
system.  
 
Results: In the positive cases, ezrin were expressed in 
epithelial cells. The statistical analysis demonstrated that the 
significant difference in the positive rate of ezrin between 
type B1 thymoma and type B3 thymoma (Z=-2.963, P= 
0.003). However, there is no difference between ezrin 
expression in type B1 and B2 thymoma (Z=-1.814, P=0.070) 
or between type B2 and B3 (Z=-1.047, P=0.295). The ezrin 
showed a tendency to be expressed in higher classification 
tumors from type B1 to B3. There is correlation between 
ezrin and WHO classification from type B1 to type B3 
(Spearman’s correlation coefficients: 0.515, P=0.002). 
Statistical analysis showed that there is correlation between 
ezrin expression and clinical stage (Spearman’s correlation 
coefficients, Ezrin: 0.481, P=0.032;). 
 
Conclusion: In all, these results suggest that the elevated 
expression of ezrin, likely contribute to the discrimination of 
type B1, B2 and B3 thymoma tissues. Moreever, the above 
results showed that the increased expression of ezrin were in 
accordance with the tumor aggravation. 
 
Keyword: Thymoma; Ezrin; Tissue array; 
Immunohistochemistry. 
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P1.12: CLASSIFICATION OF THYMIC 
NEUROENDOCRINE CARCINOMAS BY A KI67-BASED 
DIGITAL IMAGE PROCESSING APPROACH 
Cleo-Aron Weis1, Benedict Griessmann1, Philipp 
Ströbel2, Alexander Marx1  
1Institute Of Pathology, University Medical Centre Mannheim, 
Mannheim/GERMANY, 2Institute Of Pathology, University 
Medical Center Göttingen, Göttingen/GERMANY 
Background: The 2003 WHO-classification of 
neuroendocrine carcinomas (NEC) in the thymus is based on 
the nomenclature of neuroendocrine tumour occurring in the 
lung distinguishing typical carcinoid, atypical carcinoid, large 
cell neuroendocrine carcinoma (LCNEC) and small cell 
carcinoma (SCC). The classification of NEC especially 
pulmonary ones further developed in the last years. 
Meanwhile, the ki67-index has been suggested as an 
alternative approach to classify pulmonary NEC. In the 
thymus respective data are missing. In the present study we 
describe a method to automatically measure the ki67-index. 
Our aim is to correlate the classification of thymic NEC with 
the obtained ki67-index. 
 
Methods: The patient collective comprises 35 cases of 
confirmed thymic NEC. These were assigned according to 
the actual WHO-criteria (morphology, necrosis, mitoses) to 
typical carcinoid, atypical carcinoid, LCNEC and SCC. 
Evaluation of the ki67-index for these cases was based on 
digital image processing. Therefore, the 
immunohistochemically stained sections were fully digitalized 
using an Aperio ScanScope.  
 
Fig.: Image processing workflow A shows the original image. 
B visualizes the segmentation of brown nuclei whereas C 
shows the segmentation of all nuclei. Subsequently, the 
slides underwent further processing using MATLAB, which 
resulted in two binary images, one comprising all nuclei 
stained for ki67 (B) and another one comprising all nuclei 
(C). The number of nuclei per binary image can be easily 
calculated by implemented functions and the ki67 can be 
calculated by dividing the results. This method was validated 
by comparing the results of evaluation by hand and by image 
processing. 
 
Results: Digital image processing based calculation of the 
ki67-index in thymic NEC is possible and leads to similar 
results as by-hand evaluation. Furthermore, there is a good 
inter- and intraobserver reproducibility of the results. 
 
Conclusion: The ki67-index can be calculated in a full 
automatic way and leads to reliable results. In analogy to the 
recent development in pulmonary NEC, we are going to map 
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the classification by individual ki67-indeces. Thereby, we 
plan to define certain thresholds for the classification of 
thymic NEC. The numeric values of these thresholds will be 
compared to the pulmonary ones to confirm the 
commonalities or, if the results are different, to question 
them. 
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P1.13: RYTHMIC: A NATIONWIDE NETWORK FOR 
THYMIC MALIGNANCIES IN FRANCE 
 
Benjamin Besse1, Eric Pichon2, Pascal-Alexandre 
Thomas3, Hervé Léna4, Eric Dansin5, Gilbert Massard6, 
Gérard Zalcman7, Julien Mazières8, Luc Thiberville9, 
Virginie Westeel10, Pierre Fournel11, Christelle Clément-
Duchêne12, Xavier Quantin13, Jaafar Bennouna14, Thierry 
Molina15, Nicolas Girard16  
1Institut Gustave Roussy, Villejuif/FRANCE, 2Centre 
Hospitalier Régional Universitaire, Tours/FRANCE, 
3Assistance Publique, Hôpitaux de Marseille, 
Marseille/FRANCE, 4Centre Hospitalier Universitaire, 
Rennes/FRANCE, 5Centre Oscar Lambret, Lille/FRANCE, 
6Hôpitaux Universitaires de Strasbourg, 
Strasbourg/FRANCE, 7Centre Hospitalier Universitaire, 
Caen/FRANCE, 8Centre Hospitalier Universitaire, 
Toulouse/FRANCE, 9Centre Hospitalier Universitaire, 
Rouen/FRANCE, 10Centre Hospitalier Régional Universitaire, 
Besançon/FRANCE, 11Institut de Cancérologie Lucien 
Neuwirth, Saint-Priest en Jarez/FRANCE, 12Centre 
Hospitalier Universitaire, Vandoeuvre-les-Nancy/FRANCE, 
13Centre Hospitalier Universitaire, Montpellier/FRANCE, 
14Institut de Cancérologie de l’Ouest, Nantes/FRANCE, 
15Assistance Publique-Hôpitaux de Paris, Paris/FRANCE, 
16Hospices Civils de Lyon, Lyon/FRANCE 
 
Background: RYTHMIC (Réseau tumeurs THYMiques et 
Cancer) is a nationwide network for thymic malignancies, 
which was appointed in 2012 by the French National Cancer 
Institute, as part of its rare cancer program. The objectives of 
the network include a territorial coverage by regional expert 
centers, the dissemination of highest standards for the 
diagnostic and therapeutic management of patients, and the 
promotion of collaborative research. Registration in 
RYTHMIC of all patients diagnosed with thymic malignancy 
is recommended as part of good clinical practice for 
oncologists.  
 
Methods: Starting January 2012, the management of all 
patients diagnosed with thymic malignancy in France has 
been discussed on a real-time basis at a reference national 
multidisciplinary tumor board (MTB), which is organized 
twice a month using a web-based conferencing system. 
Decision-making is based on consensual recommendations, 
that were originally established using available evidence, and 
are updated and approved each year by all members of the 
network. A prospective database of all patients is hosted by 
the French Thoracic Cancer Intergroup. We report the 
characteristics and treatment modalities of patients included 
during the first year.  
 
Results: From January to December 2012, 257 patients 
were enrolled in RYTHMIC. There were 126 (49%) men and 
131 (51%) women; mean age at diagnosis was 54.5 years. 
Among 214 cases, histology was thymoma for 146 (56%) 
patients (11 (5%) type A, 28 (13%) type AB, 22 (10%) type 
B1, 35 (16%) type B2, 24 (11%) type B3, 26 (12%) mixed 
type), and thymic carcinoma for 33 (15%) patients, 8 of 
which were neuroendocrine carcinomas; other histologies 
were diagnosed for 35 (16%) patients. Among 144 cases, 
Masaoka-Koga stage was I, IIA, IIB, III, IVA, and IVB in 34 
(24%), 19 (13%), 20 (14%), 22 (15%), 35 (24%), and 14 
(10%) patients, respectively. 44 (17%) patients presented 
with autoimmune disorder, consisting of myasthenia gravis in 
28 cases. Surgery was performed for 166 patients, mostly 
using a median sternotomy approach (52% of cases). 
Postoperative radiotherapy was delivered to 42 patients; 71 
patients received perioperative chemotherapy. Exclusive 
chemotherapy/radiotherapy was administered to 20 and 4 
patients, respectively. Mature data will be presented at the 
meeting.  
 
Conclusion: This first analysis of the RYTHMIC prospective 
cohort demonstrates the feasibility of a national MTB for 
thymic malignancies, that, besides ensuring all patients an 
equal access to highly specialized treatment, provides with a 
comprehensive tool to monitor dedicated actions to improve 
the management of patients in the future, increase the 
quality-of-care, and screen patients for future translational 
research and clinical trials. Supported by Institut National du 
Cancer  
 
Keywords: network, Tumor board, thymic tumor 
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P1.14: RESULTS AND PROGNOSTIC FEATURES OF 
RECURRENT THYMOMA 
 
Cai Xu, Qin Feng, Cheng Fan, Yi Zhai, Yi Chen, Hong 
Zhang, Ze Xiao, Zong Zhou, Jun Liang, Zhou Hui, Dong 
Chen, Jie He, Lu Wang  
Radiation Oncology Department, Cancer Institute & Cancer 
Hospital Chinese Academy of Medical Science, Peking 
Union Medical College, Beijing/CHINA 
 
Background: This study sought to analyse the results and 
prognosis of recurrent thymoma. 
 
Methods: Between 1991 and 2012, 32 patients who 
developed recurrence after radical resection of thymoma 
were reviewed.  
 
Results: The initial Masaoka staging was stage I, 3; stage II, 
14; stage III, 10; stage IVa, 4;and stage IVb, 1. World Health 
Organization tumor type: A and AB, 5; B1, 7; B2, 6; B3, 12; 
and unknown, 2. Among the 32 patients, relapses were 
found in the following sites: pleura (20 cases), tumor bed 
(10),non-tumor bed in mediastinum (one), lung (seven), 
chest wall (six), lymph node metastasis (four) , abdominal 
node metastasis (one),liver (one), pleural effusion (four), and 
overlapped recurrence (14).The patterns of recurrence: local 
recurrence, 6; regional recurrence, 8; distant recurrence, 5; 
local and regional recurrence, 6; regional and distant 
recurrence, 4; local, regional and distant recurrence, 3. The 
median recurrence interval was 42 months (range, 5–193 
months). The median follow-up time after recurrence was 
49.5 months (range, 1-136months). Overall 5-year survival 
after recurrence was 65.5%. 7 patients with relapse in the 
thorax are still alive after re-resection, with a median survival 
time of 26 months (range, 6-95 months). The perioperative 
mortality was 0% and the morbidity was 14%. 4 patients with 
local relapse were given radiotherapy (RT) alone, with a 
median survival of 60 months (range, 51-107months) and 
one was dead of progressive disease, probably due to lower 
reirradiation dose (50Gy), compared to others with radiation 
dose (60Gy). In patients with regional and/or distant relapse, 
6 patients received chemotherapy, and had 37.5% of overall 
5-year survival. 5 patients without re-treatment had 50% of 
overall 1-year survival, with median survival 3 months 
(range,1-20months). After re-treatment, 9 patients had re-
relapse, and the re-relapse free survival rate was 63% at 5 
years, with a median re-relapse free survival of 53 months 
(range, 11-69months). 1 of 15 patients with RT had radiation 
pneumonitis and recovered after management. In univariate 
analysis, age (<55y, 55y; p=0.009), patterns of relapse 
(p=0.042), and recurrence-free interval (<20months, 
20months; p=0.038) were prognostic factors.  
 
Conclusion: Reoperation for resectable thymoma 
recurrences is associated with better outcome and relative 
safety, and it should be recommended. In patients with local 
recurrence of thymoma, RT may get comparable survival to 
re-operation. RT/CT probably is the treatment of choice 
when re-resection is not feasible. Younger age, local and 
regional recurrence, and longer relapse-free interval are 
associated with positive prognosis. 
 
Keyword: Recurrent Thymoma, Management, outcomes, 
Prognosis. 
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P1.15: CLINICAL OUTCOMES AND PROGNOSTIC 
FACTORS FOR PATIENTS WITH MASAOKA STAGE III 
THYMOMA 
 
Chengcheng Fan1, Qin Feng1, Yi Chen1, Yi Zhai1, Zong 
Zhou1, Dong Chen1, Ze Xiao1, Hong Zhang1, Jun Liang1, 
Ji Lv1, Zhou Hui1, Jie He2, Lu Wang1  
1Radiation Oncology, Cancer Hospital, Chinese Academy of 
Medical Sciences and Peking Union Medical College, 
Beijing/CHINA, 2Thoracic Surgery, Cancer Hospital, Chinese 
Academy of Medical Sciences and Peking Union Medical 
College, Beijing/CHINA 
 
Background: We aimed to analyze the long-term survival 
rates, recurrence rates and prognostic factors for patients 
with Masaoka stage III thymomas. 
 
Methods: A total of 111 patients with stage Υ thymoma 
treated in our hospital between January 1966 and December 
2010 were retrospectively analyzed. Sixty-eight patients 
(61.3%) were with complete resection, while 23 patients 
(20.7%) with incomplete resection and 20 patients (18%) 
with pure biopsy (18 patients with thoracic exploration 
surgery and 2 patients with CT-guided fine needle puncture 
biopsy). Fifty-six patients with complete resection (50.5%) 
and 10 patients with incomplete resection (9%) had 
postoperative radiation. Twenty patients with pure biopsy 
received post or preoperative radiation or chemotherapy with 
or without surgery. 
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Results: The median follow-up time was 66 months (5-540). 
The total overall survival (OS) ratesޔdisease free 
survival㧔DFS㧕rates and disease specific survival (DSS) 
rates at 5 and 10 year were 75.3%ޔ60.8%ޔ81.9% and 
54.7%ޔ41.3%ޔ67.1%, respectively. The total failure rate 
was 36% (40/111), including 30.6% locoregional recurrence 
and 9% distant metastasis. The DFS at 5 and 10 year among 
the patients with complete resectionޔincomplete resection 
and pure biopsy were 73.9%ޔ40.1%ޔ41.2% 
and51.5%ޔ26.7%ޔ30.9%, respectively㧔p=0.003㧕. The 
DSS at 5 and 10 year were 93.9%ޔ69.2%ޔ59.7% and 
78.9%ޔ46.2%ޔ59.7%, respectively㧔p=0.004㧕. On 
multivariate analysis, resection completeness (p=0.000) and 
lung involvement (p=0.024) were independent prognostic 
factors for DFS, and resection completeness (p=0.002)ޔage 
(p=0.028) and myasthenia gravis (p=0.038) were 
independent prognostic factors for DSS. 
 
Conclusion: Patients with completely resected thymoma 
had a better survival and lower recurrence rates than 
patients with tumor incompletely resected. Resection 
completeness and lung involvement were prognostic factors 
for DFS, and resection completenessޔage and myasthenia 
gravis were  
prognostic factors for DSS. 
 
Keywords: thymoma, Surgery, radiotherapy, thymic tumor 
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P1.16: A GENE SIGNATURE TO DISTINGUISH THYMIC 
CARCINOMA FROM THYMOMA 
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Biosciences Incorporated, Friendswood/UNITED STATES 
OF AMERICA, 3St. Joseph's Hospital And Medical Center, 
The DNA Diagnostics Laboratory, Phoenix/UNITED STATES 
OF AMERICA, 4Indiana University Simon Cancer Center, 
Indianapolis/UNITED STATES OF AMERICA, 5Pathology & 
Laboratory Medcine, Indiana University School of Medicine, 
Indianapolis/UNITED STATES OF AMERICA, 6Surgery, 
Indiana University School of Medicine and Simon Cancer 
Center, Indianapolis/IN/UNITED STATES OF AMERICA, 
7Hematology/oncology, Indiana University School of 
Medicine and Simon Cancer Center, Indianapolis/IN/UNITED 
STATES OF AMERICA 
 
Background: Thymomas and thymic carcinomas (TCs) are 
rare epithelial tumors derived from the thymic gland that can 
be at times histologically difficult to distinguish from each 
other. However, thymic carcinomas are more aggressive and 
metastasize more frequently than thymoma. Our prior work 
has resulted in the development of a commercially available 
prognostic 9-gene signature that can accurately identify 
patients at high or low risk for metastases from thymomas 
(Gökmen-Polar et al. PLoS One, 2013; in press). However, 
the signature is not prognostic for TCs (J Clin Oncol 31, 2013 
(suppl; abstr 7605)) highlighting the need to reliably 
distinguish thymomas from TCs. In the current study, we 
sought to identify molecular characteristics that distinguish 
thymomas and TCs.  
 
Methods: qRT-PCR assay for 23 genes (19 test and four 
reference genes) was performed on formalin-fixed, paraffin-
embedded primary thymomas (n=111) and TCs (n=35) 
including neuroendocrine carcinomas. All procedures were 
carried out under CLIA approved and CAP accredited 
laboratory guidelines. Expression data and biostatistical 
analysis were performed using JMP Genomics (SAS). 
Predictive modeling using Radial Basis Machine (RBM) 
analysis was performed. 
 
Results: Median ages for the thymoma and TCs cohorts 
were 49 years (range 18-85; Male:Female 1:1.5) and 54 
years (range 22-81; Male:Female 1.2: 1), respectively. The 
distribution for thymoma WHO schema consisted of 37 type 
B2 and 17 type B3, whereas type A, AB and B1 exhibited 
less aggressive type with being 8, 26 and 22, respectively. 
A12-gene signature was found to have strong diagnostic 
accuracy for identifying thymomas and thymic carcinomas. 
RBM analysis using the 12-gene signature distinguished the 
two malignancies with 100% accuracy (ROC=1.0). 
Resampling of the data was performed to validate the ROC 
accuracy using 5-fold cross-validation, repeating the 
validation 20 times. The 12-gene model had a corrected 
ROC = 0.962, with a mean accuracy of 87%. 
 
Conclusion: A diagnostic gene expression profile was 
identified that can accurately distinguish thymomas and 
thymic carcinomas. This objective molecular classification 
can assist in the accurate categorization of difficult cases 
and add valuable information to current WHO histological 
schema. The accurate classification of tumors will not only 
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enable better prognostication of tumors but also lead to more 
effective, and precise treatment options for patients. 
 
Keywords: gene signature, thymoma, thymic carcinoma, 
distinction 
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P2.01: PERCUTANEOUS CRYOABLATION IN 
TREATMENT OF RECURRENT THYMOMA: EFFICACY 
AND SAFETY. 
 
Fereidoun Abtin1, Leyla Nasehi1, Robert Suh1, Simon 
Han1, William Hsu1, James Sayre1, Robert Cameron2  
1Radiology, UCLA, Los Angeles/UNITED STATES OF 
AMERICA, 2Thoracic Surgery, UCLA, Los Angeles/UNITED 
STATES OF AMERICA 
 
Background: Thymoma is the most common anterior 
mediastina tumor (incidence: 0.15 - 0.5 in 100,000 person 
year). Following resection, recurrence occurs mostly in 
pleura or mediastinum, with re-resection as standard of care. 
Not all patients are candidates for re-resection and often 
multiple sites or recurrence limits surgical intervention. 
Percutaneous Cryoablation Technique (PCT) is a locally 
ablative minimally invasive technique, which has been used 
in management of lung cancer and metastasis with relative 
success. Here we describe our experience with use of PCT 
in management of recurrent Thymoma, and assess this 
procedure’s safety and efficacy. 
 
Methods: This is a retrospective observational study of 
thymoma patients with recurrence and drop metastasis after 
thymectomy treated with PCT from 2008 to 2012. Patients 
were followed up with imaging. Imaging was used as 
indicator of local recurrence. Multiple technical and clinical 
variables were assessed and stepwise multiple variable 
logistic regression model was used to identify significant 
imaging and clinical predictors of local control. Safety 
spectrum of Cryoablation was also assessed. 
 
Results: PCT was performed on 5 patients with 25 lesions 
(1-16 per patient) at: 8 (32%) Chest wall , 12 (48%) pleura , 2 
(8%) mediastinum and 3 (12%) lung lesions. Conscious 
sedation was used for 19 (76%) and general anesthesia for 
6(24%) ablations, with 1-3 (median:1) ablations per session. 
Median hospital stay was <1 day and it didn’t exceed 2 days. 
Median 2 freeze cycles (range 2-6) per lesion for median 
duration of 20 minutes (range 10-40). Median size of tumor 
at long axis was 34.6 mm (range 12-81) and at short axis 
was15.4 mm (6-25). 5/25 (20%) cryoablations had 0 mm 
margin, 3/ 5 cryoablations were on single lesion abutting 
aorta which recurred twice. Patients were followed up for 
median 331 days (Range=14-1495). On follow up imaging 
2/25 (8%) recurred as shown by increased size and nodular 
enhancement. Immediate complications was absent in 23/25 
(92%) ,with 1 pneumothorax and 1 pulmonary hemorrhage. 
After 24 hours 5/25 (20%) ablations had following 
complications: 1 pneumonitis, 1 pain, 2 (8%) rib fracture, 1 
myasthenia gravis flare, and 1 delayed pneumothorax and 
moderate left pleural effusion requiring thoracenthesis. 
 
Conclusion: Percutaneous cryoablation for metastatic 
thymoma allows treatment of multiple lesions with (23/25) 
92% local control rate. Proximity of tumor to aorta is possible 
cause for sink effect and local recurrence. The complications 
are limited and managed during the ablation. 
 
Keywords: Thymoma treatment, Thymoma recurrence, 
Percutaneous Cryoablation Technique, minimal invasive 
surgery 
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P2.02: AN OBSERVATIONAL DATABASE ON THYMOMA 
PATIENTS FOR STUDYING CRYOABLATION 
OUTCOMES 
 
Simon Han1, Leyla Nasehi2, Fereidoun Abtin2, William 
Hsu1  
1Medical Imaging Informatics - Dept Of Radiological 
Sciences, University of California, Los Angeles, Los 
Angeles/UNITED STATES OF AMERICA, 2Radiology, 
University California Los Angeles, Ronald Reagon hospital, 
Los Angeles/UNITED STATES OF AMERICA 
 
Background: Increasingly, electronic health records have 
become an important source for clinical phenotypes in 
understanding the natural course of diseases and the 
effectiveness of treatments. The objective of this work is to 
implement an observational database for capturing and 
standardizing detailed clinical information about individuals 
treated for thymomas at our institution. We have developed a 
web-based application for inputting, storing, and reviewing 
data on thymoma patients for the purposes of knowledge 
discovery and outcomes analysis. The platform was 
designed to be extensible to other cancers (e.g., 
mesotheliomas) and has been demonstrated as part of a 
retrospective study of percutaneous cryoablations (PCT) 
study (Abtin et al, 2013). A standardized vocabulary was 
created to represent each variable and presented as a series 
of dropdown menus to facilitate data entry, reduce errors, 
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and eliminate variability in reporting. Physicians and fellows, 
the primary users, were involved in defining the data 
elements and refining the user interface (UI). 
 
Methods: The database was implemented using an iterative 
approach. First, clinical investigators were asked to define a 
set of relevant variables and standardized set values. 
Refinement to the database was guided by feedback 
provided by clinicians who reviewed the data model and 
web-based UI. A fellow extracted patient records for 
retrospective data and organized the variables into 
categories, as well as listing expected values and 
standardizing them to ensure the consistency of data. The 
lists are set up in the database to be easily modifiable. Non-
standardized values can be entered via selection of “Other” 
and entering a user defined value. An automated information 
extraction pipeline using the Unstructured Information 
Management Architecture (UIMA) is being explored to 
automate some of the annotation tasks (e.g., extract patient 
characteristics, cryoablation details, complications). 
 
Results: A total of 89 data elements are grouped into the 
following categories: demographics (e.g., age, gender), 
clinical characteristics (e.g., date of diagnosis, lesion 
location), procedure characteristics (e.g., complications), 
imaging characteristics (e.g., measurements, PET findings), 
and follow-up (e.g., date, outcome). Each patient is 
associated with demographic information, clinical 
characteristics, and one or more PCT procedures. Each PCT 
is associated with a description about the procedure, image 
findings, and follow-up information. Presently, the database 
contains five patients with a total of 25 PCTs and 56 imaging 
follow-ups. The web-based UI provides an intuitive means for 
inputting and validating data. A dashboard allows users to 
easily query the database and export inputted information for 
further study. 
 
Conclusion: Observational databases populated with 
structured clinical information play an important role in 
supporting research. Appropriate infrastructure that 
integrates clinical and research findings are important 
moving forward. We have developed a database that is 
configured to the specific needs of a retrospective 
percutaneous cryoablation study. While the current cohort 
size is small, our intent is to provide this database as a 
resource to the community, spur discussion on how to 
standardize data collection across institutions, and partner 
with existing efforts such as the ITMIG registry (Huang, 
2012) to provide high quality clinical, intervention, and 
outcome information for thymoma patients undergoing PCT. 
Keywords: database, web application, percutaneous 
cryoablation, PCT 
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P2.03: ORAL ETOPOSIDE IN PRETREATED ADVANCED 
THYMOMA AND THYMIC CARCINOMA. A FRENCH 
EXPERIENCE. 
 
Celine Boutros, Florence Fayard, Benjamin Besse  
Department Of Cancer Medicine, Institut Gustave Roussy, 
Villejuif/FRANCE 
 
Background: Thymomas and thymic carcinomas, also 
named thymic epithelial tumors (TET), are rare tumor 
entities. There is no standard systemic treatment for 
pretreated advanced, recurrent TET. Here, we review the 
efficacy and tolerability of oral etoposide in this setting. 
 
Methods: We reviewed the files of patients who were treated 
for TET in our institution from November 1992 through 
December 2012. Patients who received oral etoposide (25 
mg 3 times a day, 3 weeks out of 4) for advanced recurrent 
disease were included in this retrospective study. We 
assessed response rates using RECIST (Response 
Evaluation Criteria in Solid Tumors) 1.0 criteria, and 
collected overall survival (OS), progression-free survival 
(PFS), and toxicities. 
 
Results: A total of 46 patients were treated for TET. Thirteen 
patients with recurrent TET received oral etoposide. The 
median age of patients was 59 years (range 33-85). Eight 
patients (61%) had thymic carcinoma and 5 patients (39%) 
had thymoma. The median number of prior chemotherapy 
regimens was 2 (range 0-8). The median follow-up was 133 
months, and the median duration of oral etoposide treatment 
was 9 months. A partial response (PR) and stable disease 
(SD) occurred in 2 (15%) and 9 patients (70%) respectively. 
No complete response was observed. The median PFS was 
9 months. The median OS was 69 months since diagnosis 
and 40 months since the initiation of oral etoposide. Among 
patients with thymic carcinoma, 1 achieved a PR and 5 
achieved SD, whereas 2 progressed. Among patients with 
thymoma, 1 achieved PR and 4 achieved SD. The median 
PFS was 4 and 53 months for thymic carcinoma and 
thymoma cohorts, respectively. The median OS since the 
diagnosis was 50 and 169 months for thymic carcinoma and 
thymoma, whereas the median OS since oral etoposide 
initiation was 22 and 98 months for the same cohorts, 
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respectively. Grade 3 and 4 toxicities included anemia 
(15%), neutropenia (23%) and thrombocytopenia (8%). No 
toxicity-related death occurred. 
 
Conclusion: Our data suggest potential activity of oral 
etoposide in patients with pretreated thymoma and thymic 
carcinoma. The treatment is well tolerated. Additional 
evaluation of oral etoposide in this rare disease is warranted. 
 
Keywords: Thymic tumors, Recurrence, Oral etoposide, 
Response 
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P2.05: NEOADJUVANT TREATMENT WITH A NOVEL 
OCTREOTIDE (PASIREOTIDE, SOM230 LAR) IN 
PATIENTS WITH PRIMARY INOPERABLE THYMOMA 
AND/ OR LOCAL RECURRENT THYMOMA TO REDUCE 
TUMOR SIZE - STUDY DESIGN AND FIRST RESULTS. 
 
Berthold Schalke1, Lukas Kirzinger1, Rosmarie Kollanur1, 
Hendrik Dax1, Gerhard Schuierer2, Berhard Kaiser1, 
Michael Ried3, Reiner Neu4, Joerg Marienhagen5, 
Alexander Marx6  
1Dep Of Neurology At Medbo, University of Regensburg, 
Regensburg/GERMANY, 2Dep Of Neuroradiology, MEDBO, 
Regensburg/GERMANY, 3Dep Thoracic Surgery, University 
of Regensburg, Regensburg/GERMANY, 4Nuclear Medicine, 
University of Regensburg, Regensburg/GERMANY, 5Dep Of 
Nuclear Medicine, University of Regensburg, 
Regensburg/GERMANY, 6Dep Of Pathology, Universityof 
Heidelberg/Mannheim, Mannheim/GERMANY 
 
Background: Long term prognosis of patients with primary 
inoperable thymoma or local recurrent thymoma (Masaoka III 
- IVa) depends on complete resection (R0). Most thymoma 
express somatostatin receptors on the surface, detectable by 
nuclear medical methods. Octreoides have the capability to 
reduce tumor volume. In combination with corticosteroids the 
effect may be enhanced. Pasireotide (SOM230 LAR) a novel 
Octreotide, has a higher binding profile to human 
somatostatin receptor suptypes (sst), up to 30-40 times 
higher in sst1 + 5 and 5 times higher in sst3, only in sst 2the 
density is 2.5 times lower. Therefore SOM230LAR could 
offer a new treatment option for thymoma.  
 
Methods: Inclusion criteria: Patients with diagnosed 
inoperable thymoma, defined as adherence to neighbored 
organs or suspicious to infiltrate neighbored organs or local 
metastasis and R0 resection can not be expected, >18years, 
WHO A – B3, Masaoka II – IVa and a positive nuclear 
medicine detection of somatostatin receptor at the tumor and 
with no exclusion criteria. The individual treatment phase will 
last up to 6 months. The role of prednisolon as an additional 
drug in the treatment of thymoma is not clearly understood, 
therefore we used the option to start the SOM230 treatment 
if possible without prednisolon. Prednisolon may be added to 
the therapeutic regime after 8 week if the therapeutic 
response is not adequate. Primary objective is tumor 
shrinkage defined as decrease in tumor volume of 20% as 
compared to baseline. Secondary objectives are resection 
status (R0,R1,R2), evaluation of morphological changes 
under treatment with SOM 230 and safety. It is a 
monocenter, single-arm, open label phase II trial.  
 
Results: The aim is to treat 16 evaluable patients, till June 
2013 8 patients started treatment, 3 patients completed 
study period regulary, 1 patient was withdrawn from the 
study because of good response so surgical removement of 
the tumor was possible, 3 patients completed the study 
regulary, 4 patients are still under treatment. Main side 
effects are gastrointestinal symptoms but always AE CTS 
are grade 2.  
 
Conclusion: Pasireotide (SOM230) offers a good chance to 
reduce tumor volu´me in patients with primary inoperable 
thymoma or local recurrent thymoma. 
Keyword: inoperable thymoma, Passireotide, SOM230 
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P2.06: COMPARISON OF VIDEO-ASSISTED 
THORACOSCOPIC SURGERY AND MEDIAN 
STERNOTOMY APPROACHES FOR THYMIC TUMOR 
RESECTIONS AT A SINGLE INSTITUTION 
 
Zhitao Gu1, Teng Mao2, Wenhu Chen1, Wentao Fang1  
1Department Of Thoracic Surgery, Shanghai Chest Hospital, 
Shanghai/CHINA, 2Department Of Thoracic Surgery, 
Shanghai Chest Hospital, Shanghai/CHINA 
 
Background: Surgical approaches for thymic tumors remain 
controversial. A variety of operative approaches have been 
introduced, each with its advantages and disadvantages. 
This study was designed to evaluate the feasibility and safety 
of video-assisted thoracoscopic surgery (VATS), and to 
compare the surgical results of VATS with the standard 
median sternotomy (MS) approach.This study was designed 
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to evaluate the feasibility and safety of video-assisted 
thoracoscopic surgery (VATS),  
and to compare the surgical results of VATS with the 
standard median sternotomy (MS) approach. 
 
Methods: Between April 2010 and April 2012, the data of 
245 patients who underwent thymectomy for thymic tumors 
were prospectively collected. Among them, 93 patients with 
clinical stage I-II disease were retrospectively reviewed.  
 
Results: Resection was planned for VATS in 49 cases, and 
for MS in 44 cases. During operation, there were 3 
conversions to open surgery because of local invasion 
(conversion to thoracotomy in 1 patient, and sternotomy in 
2). No transfusion was required in any patient. There was no 
significant difference in duration or amount of postoperative 
chest tube drainage between the two groups (p>0.05). 
Operative time, blood loss during operation, average length 
of the intensive care unit stay (LIS), and length of hospital 
stay (LHS) were significantly less in the VATS group than the 
MS group (p <0.05). There were no major perioperative 
complications or mortality. No recurrence was detected 
during a median follow-up of 27 months (range, 12–36 
months). 
 
Conclusion: VATS thymectomy for early-stage thymic 
tumors is safe and feasible. In comparison with standard 
median sternotomy, the VATS approach was associated with 
a shorter ICU stay and hospital stay. Prospective 
randomized multi-institutional trials with long-term follow-up 
are needed to compare the oncological outcomes. 
 
Keywords: Video-assisted thoracoscopic surgery, median 
sternotomy, Thymectomy, Thymic tumors 
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P2.07: INDOLEAMINE-2, 3-DIOXYGENASE (IDO) AS A 
POTENTIAL THERAPEUTIC TARGET IN THYMIC 
EPITHELIAL NEOPLASMS (TENS) 
 
Vamsidhar Velcheti1, Daniel Carvajal2, Kurt Schalper2, 
Daniel Morgensztern1, Frank Detterbeck3, David Rimm2  
1Medical Oncology, Yale University, New Haven/UNITED 
STATES OF AMERICA, 2Department Of Pathology, Yale 
University, New Haven/UNITED STATES OF AMERICA, 
3Department Of Surgery, Yale University, New 
Haven/CT/UNITED STATES OF AMERICA 
 
Background: Thymic epithelial neoplasms (TENs) are rare 
mediastinal tumors with variable malignant potential and 
limited therapeutic options. Development of new treatment 
strategies for such rare diseases requires identification of 
actionable molecular targets. Indoleamine 2,3-dioxygenase 
(IDO) pathway is a mechanism for immune tolerance in 
tumors.IDO inhibitors are currently being evaluated in clinical 
trials with early signs of clinical activity. Herein, we validated 
an assay for IDO-1 measurement in formalin-fixed paraffin-
embedded (FFPE) tissue and determine the expression of 
IDO-1 in TENs and the relationship with key clinico-
pathological variables. 
 
Methods: IDO-1 protein levels were measured in 31 TENs 
from Yale New Haven Hospital between1997-2012 
represented in a tissue microarray (TMA). IDO-1 protein 
levels were determined in FFPE tissue samples using the 
mouse monoclonal antibody 1F8.2 (Millipore) and automated 
quantitative immunofluorescence (QIF). Antibody validation 
included immunoblot experiments and QIF analysis of 
human placenta (positive control) and HEK293 cells with 
inducible IDO-1 expression. TENs cases with IDO-1 levels 
above the median score were considered as high 
expressers. IDO-1 expression was correlated with clinico-
pathological variables including age, gender, tumor size, 
development of myasthenia gravis, recurrence, WHO 
histotype and Masaoka stage. The limited number of cases 
and reduced events precluded a survival analysis. 
Results: In immunoblot experiments, IDO-1 protein was 
detected as a single ~45 kDa band only in doxycycline-
treated IDO-1 expressing HEK293 cells. Similarly, IDO-1 QIF 
levels were ~3 fold higher in doxycycline-treated HEK293 
cells than in untreated parental cells. In human placental 
samples, IDO-1 staining was detected in trophoblastic cells. 
Reproducibility of IDO-1 measurement using QIF was high 
with a linear regression coefficient (R2) of 0.8 in serial TMA 
sections. In TENs samples, IDO-1 signal allocated 
predominantly in the tumor compartment and showed 
perinuclear staining pattern. Elevated IDO-1 levels were 
detected in 16 TENs cases (52%). We find no correlations 
with WHO grade and Masaoka stage, however we are 
statistically underpowered to detect any associations with 
clinical characteristics or outcomes. 
 
Conclusion: IDO-1 protein levels can be reproducibly 
measured using QIF in FFPE samples. Nearly half of TENs 
show elevated IDO-1 protein levels. IDO-1 is involved in the 
tumor-induced immune tolerance in patients with TENs and 
the therapeutic role of IDO-1 inhibitors in this patient 
population should be investigated. 
Copyright © 2013 by the International Association for the Study of Lung Cancer 42

 
Keyword: Thymic epithelial Neoplasms, IDO-1, Immune 
dysfunction 
 
 
POSTER SESSION 2 
Display Time: Saturday, September 7, 2013 – 09:00 – 15:30 
P2.08: THYMIC TUMORS: A RETROSPECTIVE REVIEW 
OF THE 10-YEAR OHSU KNIGHT CANCER INSTITUTE 
EXPERIENCE 
 
Regan Duffy1, Charles Thomas Jr2, Brandon Tieu3  
1Division Of Hematology And Medical Oncology, Oregon 
Health and Science University, Portland/UNITED STATES 
OF AMERICA, 2Department Of Radiation Medicine, Oregon 
Health and Science University, Portland/UNITED STATES 
OF AMERICA, 3Division Of Cardiothoracic Surgery, Oregon 
Health and Science University, Portland/OR/UNITED 
STATES OF AMERICA 
 
Background: Study Design: Retrospective case-series of 
thymic malignancies treated at a NCI-Designated Cancer 
Center. Objective: To describe the clinical experience of 
patients (pts) with thymic tumors (TT) evaluated at Oregon 
Health & Science University (OHSU) over a ten-year period. 
Summary of Background Data: TT are rare and poorly 
understood tumors. TT are often asymptomatic until 
advanced stage, causing significant morbidity and treatment-
related complications. Outcomes vary depending on the 
clinical stage and histologic subtype of TT. We reviewed all 
cases of TT treated at our institution over a 10 year period, 
including disease presentation and treatment response to 
inform potential future research in TT. 
 
Methods: All pts, eighteen years old or older, with TT seen 
at OHSU between January 1, 2001 and June 30, 2011 were 
used in this analysis. Subjects were eligible for inclusion if 
they were seen during this period and diagnosed with any 
malignancy arising from the thymus gland, irrespective of 
histologic subtype. Using a case series design, data were 
collected in a retrospective manner. The medical record was 
systematically reviewed for pre-specified variables, including 
demographic data, tumor histology and stage, treatment 
history, and survival data. 
 
Results: Twenty-eight pts were identified with a TT treated 
at the OHSU Knight Cancer Institute during the defined 
decade. The mean age at diagnosis was 55 yrs. 17 pts had 
thymoma (61%), 8 had thymic carcinoma (29%), and the 
remainder had other TT. Of the total cohort, the majority 
were male (61%), lifetime never smokers (61%), and 
Caucasian (96%). Nine pts had myasthenia gravis symptoms 
(32%). Symptoms at presentation were varied but many 
experienced chest discomfort/pain, dyspnea, cough, and/or 
fatigue. The majority were treated with surgery (93%) and 
radiation therapy (68%) with a mean dose of 54.2 Gy, while 
54% received at least one type of chemotherapy (range 0-5). 
The median DFS was 110 months for thymoma, 30 months 
for thymic carcinoma, and 52.5 months for the other thymic 
tumors. The median OS has not been reached for the group 
of pts. 
 
Conclusion: Using a retrospective design, we were able to 
capture the clinical course of pts with TT treated at our 
tertiary care institution over a ten-year period. Pts were 
treated with standard therapies, and survival (both disease-
free and overall) is similar to historical reports. In addition to 
longer follow-up, these data suggest additional research 
should be undertaken to better characterize associated 
causes of TT. Future research should evaluate for tumor 
genetic abnormalities potentially amenable to targeted 
interventions which may improve DFS and OS, especially for 
aggressive variants of TT. 
 
Keywords: thymic malignancies, Oregon Health and 
Science University, case-series 
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P2.09: EFFECTIVENESS OF COMBINATION OF 
CAPECITABINE AND GEMCITABINE IN PLATINUM-
RESISTANT THYMIC EPITHELIAL TUMORS 
Piera Federico, Carlo Buonerba, Pasquale Rescigno, 
Elide Matano, Lucia Nappi, Margaret Ottaviano, Filomena 
Calabrese, Vincenzo Damiano, Giuseppe Di Lorenzo, 
Giovannella Palmieri  
University Federico II of Naples, Naples/ITALY 
 
Background: Thymic epithelial tumors (TET) are a rare 
disease. Once loco-regional treatments have failed, 
platinum-based chemotherapy is employed to prolong 
survival and palliate symptoms. In November 2005, we 
started prospective multi-center trial to test capecitabine-
gemcitabine in pretreated TET. Mature results are awaited. 
We here retrospectively review all patients with TET treated 
at our Institution with this schedule.  
 
Methods: Patients with pathologically confirmed TET 
receiving at least one cycle of capecitabine-gemcitabine 
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were included in this analysis. Descriptive statistics and 
frequency counts were used to summarize characteristics of 
the study population. Median numbers were presented with 
interquartile ranges.  
 
Results: Twenty-three patients were included in this single-
center analysis. Six patients had a thymic carcinoma, while 
three, eight, two and four patients had a B1, B2, B2/B3 and 
B3 TET, respectively. Median age was 52 years (47-
58).Eleven patients were female. Gemcitabine was delivered 
at the dose of 800-1,000 mg/m2 by 30-minute infusion on 
days 1 and 8 every 3 weeks along with oral capecitabine at 
the dose of 500-650 mg/m2 twice daily on days 1 to 14. 
Fourteen patients had an ECOG performance status of 0, 
one of 2, the remaining of 1. Seven patients had an IV a 
tumor, while the remaining had a IVb tumor. All patients, 
except for three for whom capecitabine-gemcitabine was the 
first line of therapy, had received a platinum-based regimen. 
Only one patient was primary refractory, while a complete 
response was obtained in 2 patients, a partial response in 
four patients, and the remaining had stable disease. Median 
PFS was 7 months (range, 4-9). Median survival was 12 
months (6-20). Treatment was well tolerated. Twelve patients 
showed grade 3/4 toxicity, of whom two patients showed 
severe anemia, six severe neutropenia, four severe 
thrombocytopenia, two severe diarrhea and one severe 
fatigue. 
 
Conclusion: In this retrospective analysis, gemcitabine-
capecitabine was confirmed to have a high activity in TET. 
Mature results from the ongoing multicenter trial are awaited. 
 
Keyword: capecitabine gemcitabine 
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P2.10: RECURRENCE RATE OF THYMIC EPITHELIAL 
TUMORS AFTER RADICAL SURGERY 
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Background: According to the 2004 WHO classification, 
thymic epithelial tumors (TETs) comprise different 
histologies, including thymomas, thymic carcinoma, typical 
and atypical carcinoids. Histology classification of TETs has 
a dramatic impact on the prognosis and therapeutic strategy. 
We here review all TETs treated at two participating 
Institutions over the past 30 years 
 
Methods: Eligible patients had a pathologically confirmed 
TET and had at least one access at either of the two 
participating Institutions. Relevant demographic and clinical 
data were retrieved. An exploratory analysis was conducted 
using a step-wise model in patients with completely resected 
tumors to seek for factors predictive of recurrence after 
radical surgery 
 
Results: One hundred and ninety-one patients with TETs 
were included in this retrospective analysis. Eighty-eight 
were female, the remaining were male. Median age was 47 
years (range 33-59). Sixty-three patients had myasthenia 
gravis. Five had a thymic neuroendrocrine tumor, 29 had a 
thymic carcinoma, while the remaining had a thymoma. 
Eighty-eight patients were alive at the time of analysis. 
Median overall survival was 5.25 years (range, 2.28-10.5). In 
the whole sample population, 113 patients had a completely 
resected tumor with clear pathological margins. In this sub-
group of 113 patients (median age: 43, 34-53; 48 females, 
65 males), 12 had a thymic carcinoma, with 41 patients 
presenting recurrent disease after radical surgery. At 
multivariate analysis, which included age, sex, adjuvant 
chemotherapy, adjuvant radiotherapy, maximum tumor 
diameter, presence of myasthenia gravis and stage, the only 
factor significantly predictive of recurrence was tumor 
histology (thymic carcinoma vs. other histologies, odds ratio: 
3,57, 95% CI: 1,25 to 10,15; p = 0.01). 
 
Conclusion: We showed that patients with thymic 
carcinomas are at increased risk of recurrence after radical 
surgery independently on adjuvant 
chemotherapy/radiotherapy treatment. Additional therapeutic 
options are required in the adjuvant setting of completely 
resected thymic carcinomas. 
 
Keyword: thymic carcinoma, recurrence 
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P2.11: EVEROLIMUS PLUS SOMATOSTATIN ANALOGS 
IN THYMIC EPITHELIAL TUMORS 
 
Giovannella Palmieri, Elide Matano, Lucia Nappi, Piera 
Federico, Pasquale Rescigno, Carlo Buonerba, Filomena 
Calabrese, Margaret Ottaviano, Giuseppe Di Lorenzo, 
Vincenzo Damiano  
Referral Center of Rare Tumors of Campania, University 
Federico II of Naples, Naples, ITALY, Naples/ITALY 
 
Background: Although anthracycline- and platinum-based 
chemotherapy is an active treatment for Thymic epithelial 
tumors (TETs) , novel systemic therapeutic options are 
especially needed for metastatic disease, which is virtually 
incurable. On the basis of the demonstrated activity of 
everolimus and octreotide in TETs, a phase II trial is 
currenlty undergoing at the Department of Molecular and 
Clinical Oncology and Endocrinology of University "Federico 
II of Naples" with the purpose to test combination of 
everolimus and octreotide LAR in TETs. 
The mTOR complex is linked to downstream signaling of 
many soluble factors, including cytokines and growth factors, 
such as the epidermal growth factor and the insulin-like 
growth factor-1 (IGF-1). Both of these soluble factors may 
have a role in TETs biology. Although unsupported by in vitro 
experiences, these findings suggest that stimuli transduced 
by TK receptors, and consequently by mTOR, are important 
for thymoma growth, thus providing the biological rationale to 
support the use of everolimus in TETs. There is a strong 
rationale for combination therapy of everolimus with 
somatostatin analogs. In fact, the somatostatin receptors 
sst1 to sst5 activate different pathways that target the 
ERK1/2, PI3K and NOS pathways. The indirect effect of the 
sst receptors involves inhibition of the action of the receptor 
thyrosine kinases mentioned before, via tyrosine 
dephosphorylation of these receptors and/or their substrates 
and intracellular effectors. As a result, inhibition of cell 
proliferation, migration, invasion, and induction of apoptosis 
should be potentiated by combination therapy, and escape 
mechanism should be more difficult to develop. Importantly, 
we recently reported that everolimus was effective in two 
heavily pretreated patients with advanced TETs, with a 
progression-free survival longer than 1 year and minimal 
toxicity. 
 
Methods: Adult patients with histologically confirmed TET 
that is metastatic and measurable according to RECIST 
criteria. All patients must give informed consent for their 
treatment. 
The study is an open-label, nonrandomized, Italian single 
center, phase II study. The primary end point is response 
rate; secondary end points are safety, progression-free 
survival (PFS) and overall survival (OS). Treatment consists 
of oral everolimus (10 mg daily) and octreotide LAR (30 mg 
every four weeks). Treatment is continued until RECIST 
progression, unacceptable toxity or withdrawal of consent. 
Toxicity is assessed using the National Cancer Institute 
Common Toxicity Criteria (version 3.0). 
For statistical considerations and study design, the primary 
end point is objective response. The RR is expected to be 
about 25%; a total of 35 assessable patients were needed 
for a two-stage design with a type I error (alpha) of 0.05 and 
a type II error (beta) of 0.2. In the first stage, 15 patients 
were to be enrolled. If >2 responses were observed, the 
design called for an additional 20 eligible patients to be 
accrued 
 
Results: The study is ongoing. 
 
Conclusion: Although clinical and biological evidence 
strongly suggest that a combination therapy of everolimus 
and somatostatin analogs might be highly effective in TET, 
our ongoing study is the first to be carried out to verify this 
hypothesis. Everolimus and octreotide LAR may display of 
high efficacy and low toxicity in TETs. 
 
Keywords: everolimus, octreotide 
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P2.12: CONCURRENT CHEMORADIOTHERAPY 
FOLLOWED BY SURGICAL RESECTION FOR STAGE III 
THYMIC TUMORS - EARLY RESULT OF A PHASE II 
PROSPECTIVE CLINICAL TRIAL 
 
Changlu Wang1, Wentao Fang2  
1Radiation Oncology, Shanghai Chest Hospital, 
Shanghai/CHINA, 2Department Of Thoracic Surgery, 
Shanghai Chest Hospital, Shanghai/CHINA 
 
Background: The optimal treatment for invasive stage Υ 
thymic tumors remains controversial. The aim of this study is 
to assess the clinical efficiency of the trimodality approach. 
 
Methods: From Nov 2008 to Dec 2012, totally 26 patients 
have been recruited in this trial. Of these patients there were 
17 male and 9 female with mean age of 47.7(21-65). There 
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were 3 B2, 7 B3 and 16 carcinoma according to WHO 
classification. Patients were given radiation of intensity 
modulated radiotherapy at a dose of no more than 40Gy and 
a concurrent chemotherapy of docetaxol with cisplatin.(D: 
65mg/m2, d1; P: 35mg/m2, d1-d2). Patients were re-
evaluated after the induction treatment, surgical resection 
were given to those judged resectable and radical 
chemoradiotherapy (CRT)were given to those judged 
unresectable. 
 
Results: Judging by CT images, the overall response rate of 
26 patients were: complete response 3.8%; partial response 
73.1% and no response 23.1%. Tumors of 14 patients were 
removed by surgery, while the other 12 patients received 
radical CRT. The 3 year overall survival and progression free 
survival of surgical group were both 78%, and the median 
progression free survival time is 13 months. However, the 
median PFS time was only 2.5 months for 3 patients with 
undifferentiated carcinoma, even the tumors responded very 
well to induction therapy. 
 
Conclusion: Concurrent chemoradiotherapy is an effective 
and safe induction therapy for invasive stage Υ thymic 
tumors. But it is not appropriate to apply this treatment to 
those patients with high grade thymic carcinomas, such as 
undifferentiated carcinoma. 
 
Keywords: concurrent chemoradiotherapy, surgical 
resection, stage Υ 
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P2.13: A LARGE MICRORNA CLUSTER ON 
CHROMOSOME 19 IDENTIFIED BY RNA-SEQUENCING 
IS A TRANSCRIPTIONAL HALLMARK OF WHO TYPE A & 
AB THYMOMAS 
 
Milan Radovich1, Jeffrey Solzak1, Madison Conces2, 
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Jarret Glasscock3, Kenneth Kesler1, Sunil Badve4, Bryan 
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Cancer Center, Indianapolis/IN/UNITED STATES OF 
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Genomics, LLC, St. Louis/MO/UNITED STATES OF 
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University School of Medicine and Simon Cancer Center, 
Indianapolis/IN/UNITED STATES OF AMERICA 
 
Background: Thymomas are one of the most rarely 
diagnosed malignancies. The challenge of histological 
subtyping of these tumors along with an inadequate 
understanding of the transcriptional biology is a hindrance to 
the development of prescriptive targeted therapies. To 
address this, we performed comprehensive next-generation 
RNA sequencing on a set of thymomas to examine the 
transcriptional landscape of this disease and to identify novel 
molecular hallmarks which can lead to more precise 
therapeutic interventions. 
 
Methods: RNA was sequenced from 13 thymic malignancies 
and 3 normal tissues obtained from the Indiana University 
Simon Cancer Center using a Life Technologies SOLiD 
sequencer. The WHO subtypes of our samples were 
evaluated by a single pathologist (S.B.) blinded to the 
outcomes of the sequencing and include: (4) type A, (2) AB, 
(1) B2, (5) B3, (1) C, and (3) normal tissues. For gene 
expression, reads were mapped to the human genome 
(hg19) using the LifeScope software with outputs imported 
into Partek Genomics Suite for statistical analyses and 
subsequent pathway analyses was performed using IPA 9.0 
(Ingenuity Systems). Validation of microRNA expression was 
performed using an additional set of 35 thymomas and a 
custom TaqMan Low Density Array (Life Technologies). For 
cell based studies, a thymoma AB cell line (IU-TAB1) was 
used and cells were treated with a panel of PI3K pathway 
inhibitors currently in clinical trial (BEZ235, BKM120, CAL-
101, GDC-0980, GDC-0941, MK-2206, PF-04691502, XL-
147). Cell viability was assessed using the Promega 
CellTiter-Flour assay, with statistical analysis using Prism 
Graphpad. 
 
Results: Unsupervised hierarchical clustering of gene 
expression values revealed 100% concordance between 
gene expression clusters and WHO subtype. A subsequent 
unsupervised clustering of 705 precursor-microRNAs also 
showed substantial concordance between clusters and 
subtype. By analyzing the dendrograms, A & AB tumors 
were significantly different from other thymomas. Using 
differential expression analysis, a substantial differentiator 
was a large microRNA cluster on chr19q13.42 that is 
significantly over-expressed in all A & AB tumors and whose 
expression is virtually absent in the others thymomas. Over-
expression of this microRNA cluster, which is normally silent 
in adult tissues, has been documented to result in 
hyperactivated PI3K/AKT Pathway. This was confirmed 
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using pathway analysis in the form of overexpression of 
PI3K-p110, PREX2, and down-regulation of FOXO in A & AB 
tumors. Treatment of IU-TAB1 cells, the only known 
thymoma AB cell line, with a panel of PI3K/AKT/mTOR 
inhibitors resulted in marked reduction of cell viability 
suggesting sensitivity to these agents. 
 
Conclusion: Next-generation RNA sequencing showed 
concordance with the WHO thymoma histologic classification 
and support the notion that AB thymomas are a variant of 
type A thymomas. Furthermore, the expression of a large 
microRNA cluster on chr19q13.42 which affects the activity 
of PI3K pathway is altered only in type A & AB thymomas, 
suggesting the possible exploration of PI3K inhibitors in 
patients with these subtypes of tumor. 
 
Keywords: thymoma, RNA-seq, microRNA, PI3K 
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P2.14: SURGICAL TREATMENT OF THYMOMA 
 
Sebastian Winiarski1, Piotr Rudzinski1, Renata Langfort2, 
Maágorzata Szoákowska2, Tadeusz Orlowski1  
1Department Of Thoracic Surgery, National Research Institue 
of Tuberculosis and Lung Diseases, Warsaw/POLAND, 
2Department Of Pathology, National Research Institute of 
Tuberculosis and Lung Diseases, Warsaw/POLAND 
 
Background: Thymoma is a neoplasm in which surgical 
resection is the treatment of choice. 
 
Methods: A group of 116 patients with diagnosis of the 
thymoma which had surgical resection in the period of time 
between 2004 and 2012 was evaluated. 5-year survival rate 
was evaluated according to: - surgical techniques 
(sternotomy, thoracotomy, VATS thymectomy), - 
histopathological classifications and staging (WHO, Muller – 
Hermelink, Masaoka), - symptoms of myasthenia gravis, - 
postoperative treatment. 85 patients had sternotomy, 20 had 
thoracotomy and 9 had VATS thymectomy. 46 patients had 
symptoms of myasthenia gravis patients. There were 46 
A/AB tumors, 27 B1 and 35 B2/B3 in WHO histopathological 
classification.The distribution of Masaoka staging system 
was 13 in I, 90 in II, 9 in III and 3 patients in stage IV.In 
Muller – Hermelink histologic classification 26 patients had 
thymoma corticale, 6 had thymoma medullarae, 5 had 
thymoma micronodulare, 39 had thymoma mixtum and 25 
thymoma organoidum. After surgical resection 66 patients 
underwent radiation therapy and 19 patients were not able to 
get radiation therapy beacause of poor condition. 
Postoperative chemotherapy was administrated to 6 patients 
and 18 were not able to get chemotherapy. 
 
Results: Five-year survival rate for patients who had 
sternotomy was 97.6%, thoracotomy - 89.4% and VATS 
thymectomy 77.8%. 5-year survival for patients with MG was 
89% (41/46) wheras 87% - (61/70) forthose without MG. 5-
year survival rate for patients with WHO histopathological 
diagnosis was: A/AB tumors - 90.9%, B1 – 96.3%, B2/B3 – 
97.1%. Five-year survival rate for patients with Masaoka 
histopathological diagnosis was: I – 92.3%, II – 95.5%, III/IV 
– 90.9%. Five-year survival rate for patients with Muller – 
Hermelink histopathological diagnosis was: T.corticale – 
96%, T.medullare – 83.3%, T.micronodulare – 100%, 
T.mixtum – 91.8%, T.organoidum – 100%. For patients who 
underwent radiation therapy 5-year survival was 98.5%, and 
those who were not able to get radiation because of poor 
condition was significantly worse (73.3%). The same result 
was observed in the group with postoperative chemotherapy 
98% v. 71.8%. Overall 5-year survival rate for 116 patients 
with diagnosis of thymoma was 94.7%. 
 
Conclusion: Five-year survival rate after surgical resection 
of thymoma is satisfying. The results are better when 
thymectomy is performed by sternotomy than VATS. The 
prognosis in B1-3 type thymoma is better then A/AB type and 
it is confirmed by Muller-Hermelink classification. 
 
Keywords: five-year survival rate, thymoma, surgical 
treatment 
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P2.15: FAVORABLE OUTCOME OF AGGRESSIVE 
SURGERY FOR THYMIC CARCINOMA: AN EXPERIENCE 
OF 23 CASES AT A SINGLE INSTITUTION 
 
Tetsuzo Tagawa, Takahiro Nakajima, Takekazu Iwata, 
Hidemi Suzuki, Yuichi Sakairi, Junichi Morimoto, 
Takayoshi Yamamoto, Takamasa Yun, Yuki Sata, 
Toshiko Kamata, Terunaga Inage, Teruaki Mizobuchi, 
Shigetoshi Yoshida, Ichiro Yoshino  
General Thoracic Surgery, Chiba University, Chiba/JAPAN 
 
Background: Thymic carcinoma, a relatively rare entity, 
often presents locally advanced disease, or sometimes 
distant metastatic disease. The treatment strategy and 
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clinical prognostic factors have been yet to be fully 
elucidated.  
 
Methods: Clinical charts of patients with thymic carcinoma 
who underwent surgery in Chiba University Hospital, Chiba, 
Japan, were retrospectively reviewed, and patient 
characteristics, surgical results, and survival were 
investigated.  
 
Results: From 1991 to 2013, 23 patients (14 men, 9 women) 
underwent surgery at a mean age of 55 years. Preoperative 
histological diagnosis was obtained in 10 patients (43%). 
Preoperative Masaoka’s stages were stage I in 6 patients 
(26%), II in 3 (13%), III in 9 (39%), IVa in 1 (4%) and IVb in 4 
(17%). One patient had myasthenia gravis and another 1 
patient had Multiple Endocrine Neoplasia type 1. 
Neoadjuvant chemotherapy was administered to 4 patients 
(17%) including 2 stage III and 2 stage IVb. Surgical 
resection was performed by median sternotomy in 19 
patients (83%), anterolateral thoracotomy in 3 patients 
(13%), pasterolateral thoracotomy in 1 patient (4%) and 
thoracoscopic surgery in 1 patient (4%). Complete resection 
was achieved in 15 patients (65%) including 1 extrapleural 
penumonectomy. Ten patients (43%) underwent one or more 
combined resections; lung resection for 6 patients (26%), 
innominate vein resection for 6 patients (26%), pericardial 
resection for 5 patients (22%), chest wall resection for 3 
patients (13%) and phrenic nerve resection for 2 patients 
(9%). Morbidity was experienced in 7 patients (30%), 
including 2 wound infections, 1 recurrent nerve palsy and 1 
chylothorax. There were no periooperatie deaths. Eleven 
patients (48%) received post-operative therapy consisting of 
chemotherapy in 4 patients, radiotherapy in 5 and 
chemoradiotherapy in 2. WHO histologic types were 
determined by surgical patology; squamous cell carcinoma in 
13 patients (57%), well differentiated neuroendocrine 
carcinoma in 4 (17%), sarcomatoid carcinoma in 1 (4%), 
papillary adenocarcinoma in 1 (4%), lymphoepithelioma like 
carcinoma in 1 (4%) and unknown in 3 (13%). The median 
follow-up time for the 19 surviving patients was 69 months 
(range, 1-219 months). The 5-year and 10-year overall 
survival rates were 76.2% and 63.5%, respectively. The 5-
year survival rate of 15 patients who underwent complete 
resection was 88.9%. Of the 15 patients, 3 patients (20%) 
had recurrence including lung in 2 and supraclavicular lymph 
node in 1. Patients with preoperative Masaoka stage I-III 
showed significantly better survival than the patients with 
stage IV (p=0.029).  
 
Conclusion: Even in the highly malignant disease, 
aggressive surgery provides a satisfactory outcome.  
 
Keywords: thymic carcinoma, Surgery 
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P2.16: PATTERNS AND PREDICTORS OF RECURRENCE 
AFTER RADICAL RESECTION OF THYMOMA 
 
Cai Xu, Qin Feng, Cheng Fan, Yi Zhai, Yi Chen, Hong 
Zhang, Ze Xiao, Zong Zhou, Jun Liang, Zhou Hui, Dong 
Chen, Jie He, Lu Wang  
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Union Medical College, Beijing/CHINA 
 
Background: Even after complete resection, recurrence of 
thymoma is not uncommon, but the recurrent patterns 
remain controversial. This study sought to define the patterns 
and predictors of relapse after complete resection of 
thymoma. 
 
Methods: A single-institution retrospective study was 
performed of 331 patients who underwent radical resection 
of thymoma from 1991 through 2012. 
 
Results: After a median follow-up of 59 months (range, 3-
256), the recurrence rates was 6.9% (23/331). Overall 5- and 
10-year survival rates were 92.3% and 84.9%. Cancer 
specific survival rates were 95% and 89.4% at 5 and 10 
years, respectively. Recurrence-free survival rates were 
93.6% and 87.2% at 5 and 10 years, respectively. Among 
the 23 patients, relapses were found in the following sites: 
pleura (thirteen cases), tumor bed (six), lung (six), chest wall 
(four), lymph node metastasis (two) , abdominal node 
metastasis (one),liver (one), pleural effusion (three), and 
over-lapped recurrence (nine). According to the definition of 
the International Thymic Malignancy Interest Group, 10 
(43.5%) patients had local recurrence, 15 (65.2%) had 
regional recurrence, 10 (43.5%) had distant recurrence (six 
lung, one liver, one abdominal node metastasis, and two 
lymph node metastasis), and 9 (39.1%) had over-lapped 
recurrence. The difference in survival after recurrence 
between lung and regional relapse was statistically 
significant (p=0.027), but it was insignificant between lung 
and distant relapse (p=0.808). Recurrence rates correlated 
with the initial Masaoka stage: I, 1.0% (2/196); II, 9.7% 
(9/93); III, 24.2% (8/33); IVa, 42.9% (3/7); and IVb, 100% 
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(1/1). The difference in recurrence between Masaoka stage I 
and II was stastically significant (p=0.000). And they also 
correlated with World Health Organization tumor type: A and 
AB, 3.2% ( 5/154 ); B1, 6% ( 4/67 ); B2, 6% ( 3/50 ); and B3, 
22.7% ( 10/44). Tumor size demonstrated a step-up of 
recurrence at 8 cm (<8 cm, 62.8%; 8 cm, 37.2%; P=0.007). 
In multivariate analysis, Masaoka stage (p=0.005), tumor 
size (p=0.033), and WHO histology (p=0.046) were 
predictive of recurrence. 
 
Conclusion: Pleura are the most common recurrent sites. 
Recurrence in the lung had poorer survival than the regional 
relapse, it should be included in the distant recurrence. 
Regional recurrence is the most common pattern of relapse, 
but local and distant recurrences are not infrequently 
observed. Advanced Masaoka stage, larger tumor size, and 
Type B3 were risk factors of recurrence. 
 
Keyword: Thymoma, Recurrence, Patterns of Relapse, 
Predictors. 
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SURGERY FOR PATIENTS WITH ADVANCED STAGE 
THYMOMA 
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Thoracic And Cardiovascular Surgery, Yonsei University 
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Background: The treatment strategy for patients with 
advanced stage thymic epithelial tumor is still controversial. 
We reviewed our experience of induction therapy followed by 
surgery for patients with advanced stage thymic epithelial 
tumor. 
 
Methods: From 2005 to 2013, twenty patients with 
histologically confirmed thymic epithelial tumor were treated 
with preoperative chemotherapy or chemoradiation followed 
by surgery. We reviewed these patients retrospectively 
 
Results: Three patients received preoperative 
chemoradiation and 17 patients received chemotherapy (11 
PAC protocol, 5 ADOC protocol, 4 other). Complete 
resection was achieved in 13 patients (65%). There were no 
surgery related deaths. Pathologic complete response was 
achieved in one patient. 8 patients had thymic carcinoma 
(WHO histologic type C) and 12 patients had thymoma (1 
type B1, 3 type B2, 6 type B2+B3, 2 type B3). With a median 
follow-up of 31 months (range, 2 to 95 months), the overall 5-
year survival was 87.5% and 5-year freedom from 
recurrence was 13.7%. In patients with type C thymoma, 
overall 5-year survival was 75.0 %; however, 5-year freedom 
from recurrence was 0.0 %. In patients with non-type C 
thymoma, there were no mortality during follow-up period 
and 5-year freedom from recurrence was 40.0%. 
 
Conclusion: Neoadjuvant treatment followed by surgery 
might be considered in selected patients with non-type C 
thymoma. 
 
Keywords: Multimodality treatment, thymoma, neoadjuvant 
therapy 
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Jun Liang1, Zong Zhou1, Yousheng Mao2, Liqiang Zhou3, 
Lu Wang1  
1Department Of Radiotherapy, Cancer Hospital , Chinese 
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Background: Thymic carcinomas is characterized by more 
extensive local invasion, more frequent meatastasis and 
worse prognosis, compared with other subtypes of thymic 
tumor . The low incidence has precluded the development of 
randomized clinical trials. To investigate the clinical 
characteristics, treatment method a, prognosis and treatment 
induced toxicities of thymic carcinoma, we designed the 
retrospective research. 
 
Methods: From June 1962 to December 2009, 150 patients 
diagnosed as thymic carcinoma histologically or cytologically 
were treated in Cancer Hospital , Chinese Academy of 
Medical Sciences. The median age was 52 years old (ranged 
from 13 to 79). Ninety-five were male and 55 were female. 
Patients with Masaoka’s stage I, II, III, IV disease took 2.0%, 
6.0%, 44.7% and 47.3%, respectively . Radical resection 
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was pursued in 33 patients (22.0 %). One hundred and 
thirty–five patients (90.0 %) received radiotherapy with 
median dose of 60 Gy, using conventional fractionations. 
Chemotherapy was delivered in 75 patients (50.0 %) with 
median of 4 cycles. Local control and overall survival rate 
was calculated by Kaplan-Meier method. 
 
Results: The median follow up time was 12.5 years. Five-
year and 10-year local control were 81.5% and 53.8%, 
respectively. The median survival time was 44.7 months. 
Five-year and 10-year overall survival rate was 40.6 % and 
18.8%, respectively. The 5 year survival rate was 42.7%, 
27.8 % and 17.1% for patients with disease of stage III, IVA 
and IVB, respectively. Seven of the 135 patients who 
received radiotherapy suffered radiation induced 
pneumonitis. All of the 7 patients received 2D conventional 
radiotherapy. Earlier stage and total resection were 
associated with better survival in both univariate analysis and 
Cox regression. 
 
Conclusion: The prognosis of thymic carcinoma is poor. 
Masaoka staging, histology and type of tumor resection are 
significant prognosis factors. The complication of 
radiotherapy ,especially of the 3D conformal radiation was 
tolerable. 
 
Keywords: thymic carcinoma, radiotherapy 
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FOR THYMOMA - A SINGLE INSTITUTION, 30 YEAR 
RETROSPECTIVE STUDY 
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Background: Thymoma is a rare epithelial cell tumour of the 
thymus, with an incidence of 0.15 per 100 000 persons1. 
Thymic carcinomas comprise a distinct subset and have a 
greater propensity for capsular invasion and distant 
metastases when compared to thymomas. Resection is the 
standard of care for localized disease but local recurrence is 
generally incurable, thus post-operative RT is often 
employed for high risk cases. The optimal dose of RT has 
not been established, nor whether lower doses can be 
utilized in a risk-adapted fashion for cases where RT is 
recommended but the risk of recurrence is felt to be at the 
lower end of the spectrum. Use of lower dose RT may help 
reduce the chances of late RT toxicity. Our institution 
employs such a risk adapted strategy and we present here 
our long term results. 
 
Methods: Princess Margaret Cancer Center radiation and 
surgical oncology databases were queried from 1983-2012. 
Retrospective analyses using electronic patient records and 
Mosaiq radiotherapy database were performed to assess 
demographic data, clinical presentation and treatment. 
Descriptive statistics were used to report demographic data. 
Time to event analyses and correlation of outcomes with 
demographic and treatment variables are planned. 
 
Results: Details on 104 patients treated with post-operative 
radiotherapy from 1983-2012 were available. The mean age 
was 52, range 29-73. Of patients assessed, 55/104 were 
male. Masaoka-Koga stage was assessed: 6% of patients 
were stage I, 31% IIA, 21% IIB, 27% III, 10% IV and 6% 
unknown. The most common WHO grade was B2 (37%) 
followed by B1 (16%). Complete surgical resection (R0) was 
obtained in 72% patients, R1 in 21%, R2 in 2% and 5% 
unknown. Radiotherapy doses ranged from 40 Gy – 66 Gy 
delivered in daily 2 Gy fractions; 57% patients were deemed 
low risk (typically R0 resection and WHO grade B2 or lower) 
and received 40Gy while 36% received between 45-66Gy. 
Neoadjuvant or adjuvant chemotherapy was delivered to 
13% of all patients. The mean follow up period was 9.4 
years, range 0.5-25.5 years, during which 22% patients 
experienced relapse. Of these, 43% experienced regional 
recurrence, defined as an intrathoracic relapse in an area 
not-contiguous with the thymic bed or original tumour; 39% 
local (intrathoracic relapse contiguous with original disease 
or thymic bed), and 17% distant recurrence defined as 
extrathoracic or intraparenchymal pulmonary nodules. For 
patients that experienced relapse, the median time to relapse 
was 8.7 years (range 1.3-18.3 years). Of the 59 patients who 
received 40 Gy/20 fractions, 8 developed local relapse 
(13.5%). Overall survival and multivariable analyses will be 
reported as will assessment of long term toxicities. 
 
Conclusion: Risk-adapted RT prescription for patients with 
resected thymoma appears efficacious, and may result in an 
improved therapeutic ratio for these patients. Long-term, 
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randomized controlled trials are required to further identify 
patients that are best suited to this approach. 
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